1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	Nuclear genetic control of mtDNA copy number and heteroplasmy in humans
15	
16	Rahul Gupta ^{1,2,3} , Masahiro Kanai ^{2,3} , Timothy J. Durham ^{1,2} , Kristin Tsuo ^{2,3} , Jason G. McCoy ^{1,2} ,
17	Patrick F. Chinnery ⁴ , Konrad J. Karczewski ^{2,3} , Sarah E. Calvo ^{1,2} , Benjamin M. Neale ^{2,3*} , Vamsi K.
18	Mootha ^{1,2,5} *
19	
20	¹ Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts
21	General Hospital, United States
22	² Broad Institute of MIT and Harvard, United States
23	³ Analytic and Translational Genetics Unit, Center for Genomic Medicine, Massachusetts
24	General Hospital, United States
25	⁴ Department of Clinical Neurosciences & MRC Mitochondrial Biology Unit, University of
26	Cambridge, United Kingdom
27	⁵ Department of Systems Biology, Harvard Medical School, United States
28	
29	
30	Co-corresponding authors
31	

32 Abstract

33 Human mitochondria contain a high copy number, maternally transmitted genome (mtDNA) that 34 encodes 13 proteins required for oxidative phosphorylation. Heteroplasmy arises when multiple 35 mtDNA variants co-exist in an individual and can exhibit complex dynamics in disease and in 36 aging. As all proteins involved in mtDNA replication and maintenance are nuclear-encoded, 37 heteroplasmy levels can, in principle, be under nuclear genetic control, however this has never 38 been shown in humans. Here, we develop algorithms to quantify mtDNA copy number (mtCN) 39 and heteroplasmy levels using blood-derived whole genome sequences from 274,832 individuals 40 of diverse ancestry and perform GWAS to identify nuclear loci controlling these traits. After 41 careful correction for blood cell composition, we observe that mtCN declines linearly with age 42 and is associated with 92 independent nuclear genetic loci. We find that nearly every individual 43 carries heteroplasmic variants that obey two key patterns: (1) heteroplasmic single nucleotide variants are somatic mutations that accumulate sharply after age 70, while (2) heteroplasmic 44 45 indels are maternally transmitted as mtDNA mixtures with resulting levels influenced by 42 46 independent nuclear loci involved in mtDNA replication, maintenance, and novel pathways. 47 These nuclear loci do not appear to act by mtDNA mutagenesis, but rather, likely act by conferring 48 a replicative advantage to specific mtDNA molecules. As an illustrative example, the most 49 common heteroplasmy we identify is a length variant carried by >50% of humans at position 50 m.302 within a G-quadruplex known to serve as a replication switch. We find that this 51 heteroplasmic variant exerts cis-acting genetic control over mtDNA abundance and is itself under 52 trans-acting genetic control of nuclear loci encoding protein components of this regulatory 53 switch. Our study showcases how nuclear haplotype can privilege the replication of specific 54 mtDNA molecules to shape mtCN and heteroplasmy dynamics in the human population. 55

56

57 INTRODUCTION

58

59 Mitochondria are ancient organelles that contain a tiny, high copy number circular genome 60 (mitochondrial DNA, mtDNA). Sequencing of the human mtDNA in 1981 (Anderson et al., 1981) 61 revealed that it encodes 13 core protein components of the oxidative phosphorylation system, 62 as well 2 rRNAs and 22 tRNAs required for their expression. The remaining ~1100 mitochondrial 63 proteins, including all proteins required for mtDNA maintenance, replication, and transcription, 64 are encoded by the nuclear DNA (nucDNA) and imported (Rath et al., 2020). Tissues can contain 65 tens to thousands of copies of mtDNA per cell depending on cell type (D'Erchia et al., 2015). 66 Variants in mtDNA can be maternally transmitted or arise somatically, and when they co-exist 67 with wild-type molecules, lead to a state called heteroplasmy. While mtDNA maintenance is fully 68 reliant on nucDNA-encoded proteins, a systematic understanding of how nuclear genetic 69 variation influences variation in mtDNA abundance and heteroplasmy levels in humans is lacking. 70

71 Defects in mtDNA are associated with a spectrum of human diseases (Frazier et al., 2019). Since 72 the first identification of pathogenic mtDNA mutations (Holt et al., 1988; Wallace et al., 1988), 73 scores of maternally inherited syndromes have since been characterized (Ratnaike et al., 2021). 74 Mendelian forms of mitochondrial disease producing mtDNA deletion or depletion were later 75 identified and mapped to nuclear genes involved in mtDNA replication, maintenance, and 76 nucleotide balance (Nishino et al., 1999; Suomalainen et al., 1995; van Goethem et al., 2001). 77 More generally, a quantitative decline in mtDNA copy number (mtCN) and an accumulation of 78 somatic mtDNA mutations have both long been associated with aging and age-associated disease 79 (Ashar et al., 2017; Fazzini et al., 2021; Wanagat et al., 2001). Mutations in mtDNA accumulate in 80 many cancers and in a small subset of tumors fulfill criteria as "drivers" of tumorigenesis (Gopal, 81 Calvo, et al., 2018; Gopal, Kübler, et al., 2018).

82

83 Heteroplasmy dynamics are complex and presumed to be shaped by mutation, drift, and 84 selection. The mtDNA mutation rate has been reported as 10-100x higher than the nucDNA (W. 85 M. Brown et al., 1979; Thomas & Wilson, 1991), with the main non-coding region (control region, 86 CR) containing three hypervariable regions thought to be mutational hotspots (Stoneking, 2000). 87 The high copy number, elevated substitution rate, and lack of recombination have made mtDNA 88 CR variants a valuable genetic tool in anthropology and forensics, even leading to the African 89 mitochondrial "eve" hypothesis (Cann et al., 1987; Vigilant et al., 1991). Heteroplasmy can vary 90 across siblings, attributed to germline bottleneck effects, and between cell types and tissues, 91 thought to be due to random segregation and selection (Li et al., 2015; Walker et al., 2020). 92 Mechanisms underlying heteroplasmy dynamics in humans remain obscure, though classical 93 mouse studies identified nuclear quantitative trait loci (QTLs) controlling mtDNA segregation 94 (Battersby et al., 2003), suggesting a role for nucDNA variation.

95

Here, we characterize the spectrum of mtCN and heteroplasmy across ~300,000 individuals
 spanning 6 ancestry groups in UK Biobank (UKB) and AllofUs (AoU) and identify their nuclear
 genetic correlates. To our knowledge, this is the largest analysis of human mtDNA sequence to
 date. After rigorous blood cell composition corrections, we find that mtCN declines with age, is
 influenced by numerous nuclear genetic loci, and does not decline in most common diseases.

101 mtDNA heteroplasmy shows two patterns: heteroplasmic single nucleotide variants (SNVs), 102 which tend to be somatic and accumulate with age; and heteroplasmic indels, which are more 103 common than SNVs, occur most frequently in the non-coding region, do not vary with age, and 104 are quantitatively inherited as mixtures of multiple alleles along the maternal lineage. These 105 indels are present in most individuals, showing variation across the population and even across 106 single cells from one person. For the first time, we find that many heteroplasmies are influenced 107 by a shared nuclear genetic architecture nominating genes with established roles in mtDNA 108 replication and maintenance as well as mitochondrial genes with no prior links to mtDNA biology. 109 These loci are likely acting by conferring a replicative advantage to specific mtDNA sequences. 110 For instance, the most common heteroplasmy, found in more than 50% of the population, is a 111 length variant in the mtDNA CR, which controls mtCN (in cis) and itself is influenced by nuclear 112 loci (*trans*) implicated in a mitochondrial transcription/replication switch.

- 113
- 114 **RESULTS**
- 115

116 Calling mtDNA copy number and variants at scale

117 We developed mtSwirl, a scalable pipeline for calling mtDNA variants and copy number from 118 whole genome sequencing data (Methods, Supplementary note 1). We augmented a pipeline 119 previously used to analyze mtDNA variation in gnomAD (Laricchia et al., 2022), now constructing 120 self-reference sequences for each sample using homoplasmic and homozygous calls on the 121 mtDNA and reference nucDNA regions of mtDNA origin (NUMTs, Supplementary figure 1A). 122 mtSwirl shows improved mtDNA coverage, particularly among African haplogroups (Supplementary figure 1B-E), and reduced variant calls at very low heteroplasmy 123 124 (Supplementary figure 1F), indicating reduced ancestry- and NUMT-specific mis-mapping. We 125 observe high concordance of heteroplasmy estimates with the prior method used in gnomAD (R^2 126 = 0.996 for heteroplasmy > 0.05), with homoplasmies showing allele fractions now closer to 1 127 suggesting reduced influence of NUMTs (Supplementary figure 1G, Laricchia et al., 2022). We 128 used mtSwirl to guantify mtDNA traits across 274,832 individuals of diverse ancestry across UKB 129 and AoU (Supplementary figure 2, Supplementary table 1), generating >7,800,000 mtDNA 130 variant calls across all samples.

131

132 Determinants of mtDNA copy number variation

133 We began by identifying covariates of blood mtDNA copy number (mtCN_{raw}) in UKB. Our analysis 134 highlights the strong influence of blood cell composition on mtCN_{raw} (R² ~23%, Figure 1A) as 135 previously reported (Hägg et al., 2020; Hurtado-Roca et al., 2016, Supplementary figure 3C). We 136 identified several additional technical covariates including time of day, month of year, and fasting 137 duration (R² ~ 2.5%, Figure 1A, Supplementary figures 3E-3J). Following adjustment for all 138 identified covariates (Methods, Supplementary note 2, 3), we find that corrected mtCN (which 139 we term mtCN_{corr}) was unimodal in UKB across 178,134 subjects with an average of 61.66 copies 140 per nuclear genome (Supplementary figure 3D). We observed a linear decline in mtCNcorr with 141 age (Figure 1C) of approximately 2% per decade among both males and females.

142

143 We next assessed the degree to which mtCN_{corr} is under nuclear genetic control. Our GWAS 144 identified 92 linkage disequilibrium (LD)-independent nucDNA association signals across 46 loci



Figure 1. Genetic and phenotypic determinants of mtDNA copy number in UK Biobank. A. Variance explained in mtCN by blood composition, technical, and demographic correction models. Relationship of **B.** mtCN_{raw} and **C.** mtCN_{corr} as a function of age and genetic sex. **D.** GWAS Manhattan plot from cross-ancestry meta-analysis in UKB. Labeled genes were obtained either via fine-mapping or, if a credible set (CS) could not be constructed, mapping to the nearest gene. Red genes are mitochondrial or are implicated in mtDNA disease; $\dagger = CS$ variants proximal to the gene with posterior probability of inclusion (PIP) > 0.1; $\ddagger = CS$ variants with PIP > 0.9; "c" = coding variant in the CS; underline = eQTL colocalization PIP > 0.1. Asterisks above peaks on chromosome 19 and 21 correspond to GP6 and RUNX1 respectively. **E.** Table of variants in the 95% CS with PIP > 0.1 causing a protein-altering change. Red indicates mitochondria-relevant. **F.** Standardized odds ratios for log mtCN_{raw}, log mtCN_{corr}, and major blood composition phenotypes in predicting risk of selected common diseases in UKB. Inset numbers are p-values; error-bars are 95% CI. HTN = hypertension; MI = myocardial infarction; T2D = type 2 diabetes. Correlation between effect sizes for genome-wide significant lead SNPs detected for neutrophil count between neutrophil count and **G**. mtCN_{raw} and **H**. mtCN_{corr}. Error bars represent 1SE, dotted line is weighted least squares regression line, inset corresponds to regression p-value.

(Figure 1D) after cross-ancestry meta-analysis, with an estimated SNP-heritability of ~4%
 (Methods). In contrast, mtDNA haplogroup explained < 0.5% of the variance in mtCN_{corr} with only
 a few associations of small magnitude observed (Supplementary figure 4A, B). 33 nuclear loci
 showed variants with a posterior inclusion probability (PIP) of 0.1 or greater after fine-mapping

149 (Methods); 11 of these had protein-altering variants in the 95% credible set (CS) at PIP > 0.1

150 (Figure 1E) and seven showed eQTL colocalization with the assigned gene at PIP > 0.1 including 151 TFAM, MFN2, NDUFV3, and RRM1. Seven loci contained genes implicated in disorders of mtDNA 152 maintenance, six of which harbored variants with PIP > 0.1. Prioritized genes (Methods) encoded 153 proteins that participate in the mtDNA nucleoid and replisome (TFAM, POLG2, TWINKLE, 154 TOP1MT, LONP1), nucleotide metabolism (RRM1, RRM2B, DGUOK, AK3, SLC25A5), and 155 mitochondrial fusion (MFN1, MFN2). The PNP/APEX1 locus was notable as these adjacent genes 156 encode proteins in nucleotide metabolism and mtDNA repair, neither of which has been 157 implicated in mtCN control. Fine-mapping implicated both genes, even identifying a missense 158 variant in APEX1 at PIP > 0.9 (Supplementary figure 5A). Several additional loci included 159 mitochondrial proteins with no prior links to mtDNA (SLC25A10, MCAT, MIEF2, NDUFV3). 160 Telomerase (TERT) is in the vicinity of one locus, however fine-mapping did not provide additional 161 evidence for its causality (Supplementary table 3).

162

We next tested mtCN_{corr} for heritability enrichment in genes associated with organelles or organs using stratified LD-score regression (S-LDSC, Finucane et al., 2015, 2018; Gupta et al., 2021), Methods). Encouragingly, the most significant organelle enrichment was seen for the mitochondrion (Supplementary figure 4C). Across organs, skeletal muscle and whole blood were top scoring (Supplementary figure 4D). Whole blood enrichment is expected given the sampling site, but skeletal muscle enrichment was unexpected and may be due to shared patterns of gene expression between blood and muscle or non-cell autonomous control of blood mtCN.

170

171 Blood cell composition confounds prior genetic and phenotypic associations with mtCN

172 Although many prior studies have reported associations between low blood mtCN and common diseases (Ashar et al., 2017; Chong et al., 2022; Fazzini et al., 2021; Yang et al., 2021), we could 173 174 not replicate these results using mtCN_{corr} in UKB for type 2 diabetes, myocardial infarction, 175 stroke, hypertension, or dementia (Figure 1F). We tested 24 other common diseases and only 176 observed lower mtCN in individuals with osteoarthritis (Supplementary figure 3K). Upon 177 repeating this using mtCN_{raw}, without adjusting for blood composition, we recovered these prior 178 associations (Figure 1F, Supplementary figure 3K). Even the oft-reported elevated mtCN in 179 females (Ding et al., 2015) appears to be largely driven by blood composition (Figure 1B, 1C). Our 180 genetic analyses underscore the confounding effects of blood composition in previous work. We 181 replicated (at $p < 5*10^{-5}$) 70 of the 96 previously reported mtCN GWAS loci (Longchamps et al., 182 2021) using mtCNcorr, with 37 at genome-wide significance (GWS) (Methods). However, we recover 12 additional loci from this prior study at GWS using mtCN_{raw} including loci containing 183 184 HBS1L-MYOB, C2, HLA, GSDMC, and CD226, which are linked to blood cell types and inflammation 185 (Supplementary figure 4F). In contrast, associations near TFAM, a well-known mtCN controlling 186 gene (Ekstrand et al., 2004), strengthen by ~40 orders of magnitude following blood composition 187 correction. It has long been known that inflammation is associated with cardiometabolic disease 188 (Aul et al., 2002); indeed, elevations in inflammatory blood cell indices predict elevated risk for 189 26/29 tested diseases in UKB (Figure 1F, Supplementary figure 3L). Bidirectional Mendelian 190 randomization showed that effect sizes for GWS loci for neutrophil count were strongly positively 191 correlated with corresponding mtCNraw effect sizes (Figure 1G) while the converse did not convincingly hold (Supplementary figure 4G), suggesting that changes in blood cell composition 192 193 cause mtCN_{raw} changes rather than the reverse. Importantly, neutrophil count effect sizes did not 194 predict corresponding mtCN_{corr} effect sizes (Figure 1H, Supplementary figure 4H). The most

195 parsimonious explanation for our observations is that previously reported associations between

196 blood mtCN and common diseases are, in many cases, secondary to blood composition changes.

197





Figure 2. Nuclear genetic control of relative mtDNA coverage in the non-coding region. A. Mean per-base coverage across the mtDNA in UKB. Zoomed dropdown highlights coverage depression in the mtDNA non-coding region. Arrows correspond to stages of replication: red dashed arrow = RNA primer; black dashed arrow = transient DNA "primer" flap; black solid arrow = retained replicated DNA. Grey ribbon is +/- 1 standard deviation. CSB = conserved sequence box. **B.** GWAS Manhattan plot of the residual of the regression of mtDNA median DNA primer coverage on median RNA primer coverage. **C.** GWAS Manhattan plot of the residual of the regression of mtDNA median DNA primer coverage on median 7s DNA region coverage. Insets for **B** and **C** show 2D histograms of the correlation between the respective quantities across all individuals in UKB. Red genes are mitochondrial or are implicated in mtDNA disease; † corresponds to CS variants proximal to the gene with posterior probability of inclusion (PIP) > 0.1; ‡ corresponds to CS variants with PIP > 0.9, "c" corresponds to a missense variant in the CS; underline corresponds to eQTL colocalization PIP > 0.1. **D**. Structure of MGME1 (5ZYV) shown with bound ssDNA in dark blue, the 3₁₀ helix in pink and the T265 alpha carbon as a red sphere. Inset shows the hydrogen bond between T265 and I262.

Whole genome sequencing (WGS) yields high coverage across the 16,569 bases of the mtDNA,
but it is non-uniform (Figure 2A). We observe a coverage dip by over 50% in the major non-coding

201 segment of the mtDNA called the control region (CR), which contains the light strand promoter 202 (LSP), three conserved sequence blocks (CSBs), the heavy strand origin of replication ($O_{\rm H}$), and 203 the D-loop, which contains a stable third strand of DNA (7s DNA) (Supplementary figure 6). 204 mtDNA replication starts with RNA primer synthesis from LSP-CSBII (red dashed arrow, Figure 205 **2A**). Primed mtDNA synthesis begins at CSBII, with the nascent DNA between CSBII and $O_{\rm H}$ 206 forming a transient flap called the "DNA primer" (black dashed arrow, Figure 2A). Further 207 replication produces the persistent 7s DNA after which replication proceeds (black solid arrow, 208 Figure 2A; c.f. Falkenberg & Gustafsson, 2020). In theory, we expect the highest local WGS 209 coverage in the persistently triple-stranded 7s DNA, lower coverage in the transiently triple-210 stranded "DNA primer" region, and lowest coverage in the RNA primer region. This is what we 211 observe (Figure 2A).

212

213 We hypothesized that genetic variation in nuclear-encoded mtDNA replication machinery might 214 influence the persistence of replication intermediates in the CR. To quantify these intermediates, 215 we computed the difference in coverage between these three regions across individuals in UKB 216 (insets, Figures 2B and 2C, Methods). Upon performing GWAS and cross-ancestry meta-analysis 217 for these traits, we find that nuclear genetic variants near MGME1 associate with the degree of 218 coverage discordance between the RNA primer and the DNA primer (Figure 2B), while variants 219 near TFAM, POLG, MCAT, and MGME1 associate with the discordance between 7s DNA and the 220 DNA primer (Figure 2C). All four genes encode mitochondrial-localized proteins, and MGME1 and 221 POLG work in concert to resolve flap intermediates (i.e., the DNA primer) via exonuclease activity 222 during mtDNA replication (Uhler et al., 2016). Missense variants in POLG, MGME1, and MCAT all 223 show PIP > 0.1 after fine-mapping, and the highest PIP variant at the MGME1 locus causes 224 p.Thr265lle which disrupts a hydrogen bond within a helix-forming part of the DNA binding 225 pocket of the MGME1 exonuclease domain (Figure 2D), potentially impacting DNA binding. We 226 also identify a variant causing p.Ala303Gly in MCAT, which has no prior connection to mtDNA 227 maintenance and encodes a component of mitochondrial type II fatty acid synthase.

228

229 Intermediate disease phenotypes in carriers of pathogenic mtDNA mutations



Figure 3. Evidence of intermediate phenotypes among carriers of the MELAS variant in UKB. Table shows carrier frequencies for 10 known pathogenic mutations in UKB, including chrM:3243:A,G (pathogenic for MELAS), with heteroplasmy distributions plotted as jittered points. Panels show mean Hemoglobin A1c, triglyceride levels, auditory threshold (via speech recognition threshold test), and visual impairment (via vision test measured as logMAR) among mtDNA pathogenic variant carriers. Only points corresponding to more than 10 measurements are shown. Vertical lines represent per-trait means among individuals with none of the 10 pathogenic mutations detected.

230 We next considered mtDNA sequence variation in UKB (Methods), with an initial focus on ten 231 established pathogenic mtDNA mutations, including those associated with Leber's hereditary 232 optic neuropathy, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes 233 (MELAS), and aminoglycoside-induced ototoxicity (Figure 3). We find that ~1:192 individuals in 234 UKB carry at least one of the ten variants, in agreement with a previous estimate of 1:200 (Elliott 235 et al., 2008). A longstanding question is whether carriers of rare pathogenic mtDNA variants in 236 the population exhibit intermediate disease phenotypes, which can now be addressed thanks to 237 the rich phenotyping in UKB. We tested four phenotypes traditionally associated with these 238 mtDNA variants: hemoglobin A1c (chrM:3243:A,G), triglyceride levels (chrM:3243:A,G), hearing 239 impairment (chrM:1555:A,G, chrM:3243:A,G, chrM:7445:A,G), and visual impairment (chrM:3460:G,A, chrM:11778:G,A, chrM:14484:T,C, chrM:14459:G,A) (M. D. Brown et al., 2000; 240 241 Rydzanicz et al., 2011; Sharma et al., 2021; Shoffner et al., 1995). Individuals carrying the 242 chrM:3243:A,G variant show elevated hemoglobin A1c, elevated triglycerides, and hearing and 243 vision impairment (Figure 3, Methods). The other tested mtDNA variants were not associated 244 with deviations in these phenotypes.

245

246 Spectrum of mtDNA sequene variation across 253,583 individuals

247 Our analysis across UKB and AoU yields the largest database of mtDNA SNVs and indels to date 248 (Figure 4A). Consistent with prior gnomAD analysis (Laricchia et al., 2022), we find that the 249 number of homoplasmies per individual is closely related to haplogroup, with haplogroup H 250 (closest to GRCh38 reference) showing the fewest and haplogroup L0 showing the most 251 (Supplementary figure 7A). Heteroplasmy distributions were consistent between UKB and AoU 252 (Figure 4B, Supplementary figure 7D, 7H), and most individuals carried 0-1 heteroplasmic SNVs 253 and 0-2 heteroplasmic indels (Supplementary figure 7E). The hypervariable regions of the 254 mtDNA, found within the non-coding CR, contain an elevated heteroplasmic SNV rate and a vast 255 predominance of heteroplasmic indel variants (Figure 4A). Heteroplasmic indels primarily arise 256 near poly-C stretches (e.g., chrM:302, chrM:567, chrM:955, chrM:16182) in the non-protein-257 coding mtDNA, while coding mtDNA shows a low indel rate despite the presence of many poly-C 258 tracts (Figure 4A), consistent with negative selection. We tested the most common 259 heteroplasmies in UKB for associations with risk of 29 common diseases (Methods) and found 260 little or no evidence of association, though sample sizes were limited (Supplementary figure 7F). 261

262 mtDNA SNVs and indels exhibit distinct modes of transmission and age accrual

263 We next investigated the patterns of transmission and age-dependence for mtDNA 264 heteroplasmies. For analysis of age, we focused on AoU given the broader age range of 265 participants (20-90 versus 40-70 for UKB). While heteroplasmic SNVs tend to accumulate with 266 age (particularly after age 70), this was not the case for indel heteroplasmies (Figure 4C). Using siblings and parent-offspring pairs in UKB (Methods), we find that nearly all heteroplasmic indels 267 268 are quantitatively maternally transmitted and shared between siblings, while most 269 heteroplasmic SNVs are not (Figure 4D). The maternal transmission and stability across age leads 270 us to conclude that most indel heteroplasmies are inherited as mixtures; in contrast, for 271 heteroplasmic SNVs, the typical lack of transmission and accumulation with age strongly suggests that they typically arise via somatic mutagenesis. In contrast to prior reports, no variants showed 272 273 evidence of paternal transmission (Figure 4D). Transitions were far more frequent than

- transversions and showed a sharp increase in frequency in older age, consistent with the somatic
- 275 mtDNA mutational spectrum seen in aging brains (Kennedy et al., 2013). Curiously, we observed
- a decline in transversion heteroplasmies in older individuals (**Supplementary figure 7F**).
- 277

278 Nuclear genome GWAS for mtDNA heteroplasmy

We next sought to determine the extent to which mtDNA heteroplasmy is influenced by nuclear genetic loci. To our knowledge, nuclear genetic loci influencing individual mtDNA heteroplasmies in humans have never been reported. Given that most common heteroplasmies showed maternal transmission (**Supplementary figure 7H**), we restricted to individuals carrying each heteroplasmy and performed GWAS with the heteroplasmy level as a quantitative trait (**Figure 4B, Supplementary figure 7I**).

285

286 We identified 42 LD-independent associations across 39 heteroplasmies after cross-ancestry 287 meta-analysis of our UKB GWAS. Our results revealed a shared nuclear genetic architecture for 288 heteroplasmies across mtDNA sites, with nine of 20 unique nuclear loci associated with >1 289 heteroplasmic variant (Figure 4E, Supplementary figure 9A). Cross-mtDNA heterogeneity was 290 also observed: chrM:302:A,AC and chrM:302:A,ACC appeared most associated with loci near 291 SSBP1, TFAM, LONP1, and MCAT, while the other heteroplasmies were most strongly associated 292 with loci containing DGUOK, PNP, and POLG2. While many genes implicated in heteroplasmy 293 control were also identified in our mtCN GWAS, others were not (e.g., TEFM, POLRMT, MTPAP, 294 SSBP1, ABHD10; Figure 4E). Many associated loci were near genes with established roles in 295 mtDNA replication and maintenance (Figure 4F), with missense variants identified within the 95% 296 credible set in DGUOK, LONP1, POLRMT, MGME1, and POLG2 and eQTL colocalization PIP > 0.1 297 seen for POLRMT, POLG2, and TFAM. Of the novel hits, we highlight a locus containing C7orf73 298 (Figure 4E, Supplementary figure 9F), which encodes a protein recently linked to Complex IV 299 (Sang et al., 2022), suggesting a moonlighting role for this short protein in mtDNA maintenance. 300

301 Zooming in, we see strong effect sizes from PIP > 0.9 variants in or near genes related to 302 nucleotide metabolism (PNP, DGUOK) and DNA replication (POLG2). The likely causal variant for 303 PNP (PIP 1, Supplementary figure 9G) is in an intron of PNP and colocalizes with a strong negative 304 cross-tissue eQTL (multi-tissue $p \sim 0$; colocalization PIP 1; Supplementary figure 9H-I; Aguet et 305 al., 2020) this gene is not yet linked to mtDNA disease but performs an analogous reaction to 306 TYMP (an mtDNA disease gene) on purines. The likely causal variant for DGUOK (PIP 0.99, Figure 307 **4G**) results in a p.Gln170Arg missense change within the kinase domain, potentially disrupting 308 the tertiary structure of the protein as this glutamine side chain participates in a number of 309 hydrogen bonds and stacking interactions (Figure 4H). The putative causal variant for POLG2 (PIP 310 1, Figure 4I) results in p.Gly416Ala within a predicted anticodon binding domain. This amino acid 311 is highly conserved (Supplementary figure 9J) and the mutation impacts a loop near the POLG2 312 homodimer surface (Figure 4J). These examples highlight variants impacting proteins and 313 producing a large impact on the levels of specific heteroplasmic mtDNA variants.

314

To test if heteroplasmy-associated nuclear loci act via mtDNA mutagenesis, we repeated our GWAS re-coding heteroplasmy traits as "case/control", where for each mtDNA variant, cases showed detectable heteroplasmy and controls did not. We observed little signal (**Supplementary**



Figure 4. Pervasive nuclear genetic control over the most common mitochondrial DNA heteroplasmies. A. mtDNA heteroplasmies passing QC in UKB and AoU. Data tracks show, starting from the inside: positions of poly-C tracts; mtDNA genomic annotations (orange = HVR, yellow = rRNA genes; blue = tRNA genes; purple = coding genes); counts of heteroplasmic SNVs (red); counts of heteroplasmic indels (black). Teal arc corresponds to region highlighted in Figure 5. Light line in outermost track is a reference line at 100. B. Selected heteroplasmy distributions across UKB and AoU in individuals carrying the allele. C. Mean count of heteroplasmies per individual across age groups in AoU. Error bars are 1SE. D. Relationship between heteroplasmy levels in mother-offspring (left), father-offspring (middle), and sibling-sibling (right) for all heteroplasmies found in >5 individuals. E. GWAS lead SNPs from all common heteroplasmies with genome-wide significant signals. Point size corresponds to lead SNP pvalue; dark points are genome-wide significant. Vertical lines correspond to SNPs near genes of interest and/or loci found across multiple mtDNA variants. Green corresponds to genes nominated for mtCN, \dagger = CS variants with PIP > 0.1; \ddagger = CS variants with PIP > 0.9, "c" = coding variant in CS; underline = eQTL colocalization PIP > 0.1. F. mtDNA dynamics pathway showing genes highlighted in heteroplasmy GWAS. G. chrM:16183:AC,A heteroplasmy as a function of lead SNP genotype in DGUOK. H. Structure of DGUOK (20CP) with amino acid Q170 in red and nearby residues participating in hydrogen bonds or stacking interaction in pink. dATP shown as black sticks. I. chrM:16183:A,AC heteroplasmy as a function of lead SNP genotype in POLG2. J. Structure of polymerase gamma enzyme (4ZTU) with POLG in light blue and POLG2 subunits in green and yellow. Bound DNA is in dark blue and the POLG2 residue G416 is shown as red spheres. In panels G and I, red lines correspond to medians.

figure 9B), arguing against a mutagenic origin influenced by nucDNA variation and supporting the notion that maternal transmission determines the presence of each tested heteroplasmy, while 320 nuclear variation can influence the subsequent relative heteroplasmic fraction.

321

322 We took several steps to validate our genetic findings. We performed a replication analysis in 323 AoU across 96,698 diverse individuals and observed high concordance between cross-ancestry 324 meta-analysis effect sizes in UKB and AoU ($R^2 = 0.79$, Supplementary figure 9C) with limited 325 attenuation (as expected with Winner's curse, c.f. Lohmueller et al., 2003). We investigated 326 potential technical and biological confounders, observing little correlation between these 327 variables and heteroplasmies (Supplementary figure 8A-E, Supplementary note 2). We explicitly 328 tested the robustness of our results to the contaminating effects of NUMTs (Supplementary note 329 5), finding that GWAS effect sizes were not sensitive to mtDNA coverage as would be expected 330 for NUMT-derived signals (Supplementary figure 8J-M). Additionally, we found strong 331 correlations between UKB meta-analysis effect sizes and those from individual ancestry groups 332 in AoU despite small N ($R^2 = 0.49$ -0.78 Supplementary figure 9D), reducing the likelihood of 333 confounding by recent polymorphic NUMTs. We tested all GWAS hits for LD $R^2 > 0.1$ with variants 334 within 20kb windows of 4,736 reference and polymorphic NUMTs, finding only one concerning 335 locus – among UKB EUR, the SSBP1 locus had LD $R^2 = 1$ with variants in a reference NUMT. 336 Importantly, this locus remained significant for chrM:302:A,AC among AFR in AoU despite AFR 337 showing much lower LD with NUMT variants (Supplementary figure 9K).

338

339 Pervasive length variation in CSBII across individuals and within single cells

340 The "length heteroplasmy" at chrM:302, located within the CSBII region of the mtDNA CR (Figure 341 5A), is the most common heteroplasmic site we observed in UKB and occurs within a regulatory 342 motif for mtDNA replication (Wanrooij et al., 2010). Though the reference genome corresponds 343 to G_mAG₇ (nomenclature indicates the length of the poly-G stretch on the GRCh38 opposite 344 strand, **Figure 5A**), we frequently observe individuals harboring G_mAG_8 (chrM:302:A,AC), G_mAG_9 (chrM:302:A,ACC), and G_mAG₁₀ (chrM:302:A,ACCC). Quantitatively, the levels of these 345 346 heteroplasmies are shared between siblings (Figure 5B), indicating maternal transmission of 347 mixtures of multiple mtDNA haplotypes.

348

Most of the 156,885 individuals assessed in UKB harbor a mixture of these length heteroplasmies (Figure 5C), with individuals from different haplogroups showing different distributions (Figure 5D). The observed quantitative maternal transmission of heteroplasmy implies that mtDNA mixtures exist in individual cells, and we indeed find mtDNA mixtures at chrM:302 in 171 single cells from one individual (Figure 5E) by re-analyzing single-cell mtDNA ATAC-seq data (Methods).

355 We find multiple lines of evidence linking mtDNA replication and length variation at chrM:302. 356 Longer alleles at this site are associated with declining mtCN_{corr} with an effect size comparable to 357 the TFAM locus (Figure 5F, PIP ~ 1). GWAS for chrM:302:A,AC, the most common length 358 heteroplasmy, nominated several genes relevant for mtDNA replication and nucleotide balance 359 not identified in other heteroplasmy GWAS (CDA, MTPAP, TFAM, TEFM, LONP1, MCAT; Figure 360 4E, 5G). mtCN and chrM:302:A,AC heteroplasmy even show colocalization at the two most significant mtCN loci: 10:60145079:A,G (a TFAM 5' UTR variant) and 19:5711930:C,T (a LONP1 361 missense variant) both show a PIP ~ 1 for mtCN and have PIP > 0.3 for chrM:302:A,AC. It is notable 362 363 that prior studies have suggested that length variation at the chrM:302 site serves as a "rheostat"



Figure 5. chrM:302 length heteroplasmies are inherited maternally as mixtures, co-exist in single cells, and are under the influence of the nuclear genome. A. Scheme showing chrM:302 region inside CSBII responsible for forming a G-quadruplex structure along with length heteroplasmy G_mAG_n nomenclature. B. Sibling-sibling transmission of length heteroplasmies at chrM:302. C. Length heteroplasmy composition across all UKB individuals. D. Length heteroplasmy composition in UKB in select mtDNA haplogroups. E. Length heteroplasmy composition across 171 single cells in whole blood. Each vertical bar corresponds to a single individual (C, D) or cell (E). Colors for panels B-E correspond to legend between panels B and D. F. Effect of length of major allele at chrM:302 (red line) and TFAM fine-mapped variant (black dot) on mtCN. Error bars are 1SE. G. Case-only mtDNA heteroplasmy GWAS Manhattan plot for chrM:302:A,AC. Red genes are mitochondrial or are implicated in mtDNA disease; † corresponds to CS variants proximal to the gene with PIP > 0.1; "c" corresponds to coding variant in CS; underline corresponds to eQTL colocalization PIP > 0.1. H. chrM:302 length heteroplasmies as a function of highest PIP SNP genotype in SSBP1 locus. Red line corresponds to per-nuclear-genotype median heteroplasmy.

364 for mtDNA replication versus transcription. The G-quadruplex at CSBII (Figure 5A) is a tertiary 365 structure formed by the DNA and the nascent RNA primer which promotes DNA replication by blocking RNA polymerase progression (Wanrooij et al., 2010, 2012). In vitro studies have 366 367 suggested that CSBII G-quadruplex strength is a function of chrM:302 allele, influencing the degree to which RNA transcription switches to DNA synthesis (Figure 5A, Tan et al., 2016). For 368 the first time we now report that nuclear variants in genes related to the mtDNA replisome can 369 370 favor one length heteroplasmy over another - for example, variants near SSBP1 favor 371 chrM:302:A,ACC (Figure 5H). Taken together, our results suggest that nuclear genetic variation 372 can influence the replication efficiency of mtDNA molecules based on chrM:302 allele.

373

374 **DISCUSSION**

375

mtDNA heteroplasmy dynamics are highly complex, shaped by random drift and selection that in
 principle can operate at the level of mtDNA, mitochondria, or cells. Given that all protein

378 machinery for mtDNA replication and maintenance is encoded by the nucDNA, it has long been 379 theorized that the nuclear haplotype could influence mtDNA heteroplasmy. Classical mouse 380 genetics revealed the existence of nuclear QTLs that could influence heteroplasmic mtDNA 381 transmission (Battersby et al., 2003), though specific mechanisms and relevance to humans have 382 been lacking. Here, for the first time, by leveraging whole genome sequencing across two large 383 biobanks, we report pervasive nuclear genetic control of mtDNA abundance and heteroplasmy 384 variation in humans. Many of these nuclear QTLs involve the machinery responsible for mtDNA 385 maintenance, which likely act directly on mtDNA by altering the relative replication efficiency of 386 mtDNA molecules based on their sequence, while several others correspond to genes never 387 before linked to mtDNA biology. High statistical resolution allows us to gain detailed molecular 388 insights into the mechanisms underlying an entire battery of mito-nuclear interactions, with 389 implications for human disease, physiology, and evolution.

390

391 Our ability to dissect the genetic architecture of mtCN and heteroplasmy was possible both 392 because of the statistical power afforded by the scale of large biobanks and because of careful 393 attention given to technical and biological confounders. We analyzed mtDNA sequences across 394 274,832 individuals of diverse ancestries from two biobanks, generating the largest collection of 395 mtDNA traits to date. We were particularly attentive to the technical challenges of contamination 396 by mtDNA pseudogenes in the nuclear genome (NUMTs, Supplementary Note 5, 6). We explicitly 397 tested many potential confounders of mtDNA traits, finding that correction of mtCN for blood 398 cell composition had a profound effect on the observed association landscape. Many previously 399 reported associations between blood mtCN and cardiometabolic traits (Ashar et al., 2017; Fazzini 400 et al., 2021) disappear or reverse direction after adjustment for blood cell composition (Figure 401 **1F**). Our corrections reduce and even eliminate GWAS hits near genes suspiciously related to 402 blood cell composition and inflammation (e.g., HLA, HBS1L) seen in recent studies (Longchamps 403 et al., 2021). Our data suggest that, in many cases, an inflammatory state in cardiometabolic 404 disease influences blood cell composition, driving the previously observed decline in mtCN.

405

406 The resulting GWAS of mtCNcorr and mtDNA heteroplasmies provide new insights into mtDNA 407 maintenance. The nuclear loci we identify, including those with fine-mapped missense variation 408 (e.g., MGME1, POLG, POLG2, DGUOK, LONP1), are enriched for roles in the mtDNA nucleoid, 409 mtDNA replication, and nucleotide balance, rather than pathways previously implicated in 410 heteroplasmy maintenance in model organisms such as mitophagy or stress response (Gitschlag 411 et al., 2016; Lin et al., 2016). We show how population-level genetic analysis can produce 412 detailed, mechanistic insights into mtDNA replication: GWAS of the relative mtDNA coverage in 413 the 7S DNA "primer" highlights missense variants in both MGME1 and POLG, whose products 414 have exonuclease activity that can resolve this "flap" intermediate. We observe notable 415 differences in the genetic architecture of mtCN_{corr} and heteroplasmy, producing additional insights: while TFAM, LONP1, DGUOK, and PNP are associated with both, the former two 416 417 (encoding components of the mtDNA nucleoid) were the most significant associations for 418 mtCN_{corr}, while the latter two (involved in nucleotide balance) were among the strongest 419 associations across heteroplasmies. QTLs corresponding to TWNK were only identified for 420 mtCNcorr while associations near SSBP1, TEFM, and POLRMT were specific to heteroplasmy, 421 suggesting that genetic variation in different mtDNA replication genes can have effects specific to mtCN or heteroplasmy. We identify many loci with no prior links to mtDNA biology, such as *C7orf73, MCAT, ABHD10, NDUFV3, CDA*, and *ADA*, proposing new roles for their protein products.
The *PNP* gene product represents an excellent candidate gene for unsolved mtDNA deletion
syndromes as it performs an analogous function to *TYMP* for purines and is notable for its
association with the levels of 13 length heteroplasmy variants at three mtDNA sites.

427

428 A striking finding from our work is that nearly everyone harbors heteroplasmic mtDNA variants 429 obeying two key, previously unappreciated, principles: (i) heteroplasmic SNVs are typically 430 somatic, accrue with age sharply after age 70, and tend to be transitions, while (ii) heteroplasmic 431 indels are found in >60% of individuals, do not accrue with age, and are usually inherited as 432 mixtures within the same maternal lineage. Consistent with prior work (Stoneking, 2000), 433 heteroplasmic SNVs tend to occur more in the mtDNA hypervariable regions, but most 434 heteroplasmies detected here are inherited indels. Most heteroplasmic indels appear to occur 435 next to poly-C stretches in the non-protein coding mtDNA; heteroplasmic indel rates are orders 436 of magnitude lower next to poly-C stretches in coding regions, suggesting negative selection in 437 these regions. Strikingly, for any given common indel, we find that maternal heteroplasmy levels 438 quantitatively predict offspring heteroplasmy levels, suggesting neutral transmission. We show 439 for the first time that these heteroplasmy levels are also under nuclear genetic control, with 440 associated loci enriched for genes involved in mtDNA biology and nucleotide balance. These loci 441 are similar across heteroplasmies at multiple mtDNA sites, suggesting a shared genetic 442 architecture.

443

444 Our identified nuclear QTLs for mtDNA length heteroplasmies could, in principle, operate by one 445 of two mechanisms: (1) the associated nuclear variants are "mutagenic" and impair mtDNA 446 copying fidelity resulting in somatic indels due to slippage in poly-C tracts (Marchington et al., 447 1997), or (2) these nuclear variants confer an mtDNA replicative advantage to maternally 448 inherited mtDNA molecules carrying certain length variants. Our data favors the latter. Case/control GWAS showed very little signal compared to case-only analysis; in concert with the 449 450 observed maternal transmission this strongly suggests that the identified nuclear QTLs modify 451 existing indel heteroplasmy levels rather than acting via mutagenesis, likely by altering the 452 replicative efficiency of the mtDNA molecules carrying different alleles. Variants near POLG2, but 453 notably not POLG, were associated with heteroplasmy; POLG is the active subunit of mtDNA 454 polymerase in which mutations produce a "mutator" phenotype (Trifunovic et al., 2004), while 455 POLG2 is the accessory subunit relevant for processivity (Lim et al., 1999; Longley et al., 2006). 456

457 Our work provides insight into mechanisms by which the nuclear haplotype can confer a 458 replicative advantage to specific mtDNA variants. This is perhaps best illustrated by length 459 heteroplasmy at chrM:302. This heteroplasmy occurs within the G-quadruplex in CSBII in the 460 mtDNA noncoding region, which can induce switching from transcription to replication by 461 blocking transcription progression. Prior in vitro studies have shown that the chrM:302 length 462 polymorphism impacts the strength of this G-quadruplex hence modifying the 463 transcription/replication switch (Agaronyan et al., 2015; Tan et al., 2016). We find that mixtures 464 of mtDNA with different chrM:302 length variants are maternally inherited in more than half of 465 the population. Once inherited, we show that chrM:302 alleles influence mtDNA abundance

466 (acting in *cis*), and we find that the resulting heteroplasmy levels are influenced in *trans* by 467 nuclear QTLs (e.g., SSBP1, POLG2, TEFM) whose proteins directly operate this regulatory switch 468 (Tan et al., 2016). In sum, our results suggest that the associated nuclear variants alter chrM:302 469 heteroplasmy by influencing factors that interact with the chrM:302 G-quadruplex, thus 470 privileging the replication of mtDNA templates carrying a particular chrM:302 genotype. Recent 471 experiments in embryonic stem cells led to speculation that CSBII length variants may contribute 472 to mtDNA reversion after mitochondrial replacement therapy (MRT) (Kang et al., 2016) due to 473 replicative advantage of carryover mtDNA from the intending mother – our nuclear genetic 474 association results may provide insight into nuclear genetic control of this reversion.

475

An open question is why mtDNA heteroplasmy is so common in humans, and whether a selective
advantage preserves this variation and the observed mito-nuclear interactions. As the mtDNA
has high mutation rates with little or no recombination, it is prone to the accumulation of
disabling mutations that could lead to its "meltdown" via Mueller's ratchet (Lynch et al., 1993).
However, mtDNA mutation followed by heteroplasmy is a requisite step in evolutionary
adaptation. The identified nuclear QTLs for mtDNA heteroplasmy may represent mechanisms by
which a reservoir of such variation can be tolerated and harnessed.

483

484 **ACKNOWLEDGEMENTS**

485 We thank Anna Kotrys, Tom Barton-Owen, and Carla Winter for thoughtful discussions, Melissa 486 Walker for facilitating access to published data, Kristen Laricchia, Katherine Chao, Grace Tiao, 487 Sinéad Chapman, and Namrata Gupta for help with gnomAD data and pipelines, and Wei Zhou 488 for help with SAIGE. This project was supported in part by grants 5R35GM122455 (VKM) and 489 5F30AG074507 (RG) from the National Institutes of Health. VKM is an Investigator of the Howard 490 Hughes Medical Institute. PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), 491 and a UK NIHR Senior Investigator, who receives support from the Medical Research Council 492 Mitochondrial Biology Unit (MC UU 00028/7), the Medical Research Council (MRC) 493 International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the 494 Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's 495 Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) 496 497 and not necessarily those of the NIHR or the Department of Health and Social Care. This research 498 has been conducted using the UK Biobank Resource under Application Number 31063. The All of 499 Us Research Program is supported by the National Institutes of Health, Office of the Director: 500 Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 501 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 502 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The 503 504 Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community 505 506 Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, 507 the All of Us Research Program would not be possible without the partnership of its participants. 508

509 **COMPETING INTERESTS**

510 VKM is a paid advisor to 5am Ventures and Janssen Pharmaceuticals. BMN is a member of the 511 scientific advisory board at Deep Genomics and Neumora, consultant of the scientific advisory

- board for Camp4 Therapeutics and consultant for Merck. KJK is a consultant for Vor Biopharma.
- 513

514 DATA AVAILABILITY

515 In terms of data processed or generated as part of this study, we provide genetic association statistics for LD-independent lead SNPs and fine-mapped variants in UKB in addition to 516 517 colocalization results (Supplementary tables 2-4). Full GWAS summary statistics from UKB and 518 AoU will be made available in Zenodo upon peer-review. All GWAS sample sizes for each genetic 519 ancestry group, meta-analysis, and phenotype can be found in Supplementary table 1. AoU 520 policy does not currently permit public release of individual-level data due to important ethical 521 and privacy considerations: https://www.researchallofus.org/wp-content/themes/research-522 hub-wordpress-

- 523 theme/media/2020/05/AoU_Policy_Data_and_Statistics_Dissemination_508.pdf
- 524

525 In terms of external data used in this study, we leveraged GWAS summary statistics, and ancestry-526 specific LD-matrices, and a curated list of 29 common, high-quality disease phenotypes 527 generated as part of the Pan UKBB project (Pan UKBB Initiative, 2022), with more information 528 available online (https://pan.ukbb.broadinstitute.org). UKB phenotype and whole genome 529 sequencing data can be accessed via the UKB Research Analysis Platform after completing a UKB 530 access application: https://ukbiobank.dnanexus.com/landing. AoU phenotype and genotype 531 data can be accessed via access to the Controlled Tier v6 on the AoU researcher workbench: 532 workbench.researchallofus.org. Published mtscATACseq data used for chrM:302 analysis can be 533 obtained via approval from dbGaP. Gene-sets for enrichment analyses can be obtained using 534 COMPARTMENTS (https://compartments.jensenlab.org) and MitoCarta 2.0 535 (https://www.broadinstitute.org/files/shared/metabolism/mitocarta/human.mitocarta2.0.html 536) as described previously (Gupta et al., 2021). The GRCh37 and GRCh38 reference genomes as 537 well as other standard reference data are available via the GATK resource bundle: 538 https://gatk.broadinstitute.org/hc/en-us/articles/360035890811-Resource-bundle. Annotations 539 for the baseline v1.1 and BaselineLD v2.2 models for S-LDSC as well certain other relevant 540 reference data, including HapMap3 SNP list, can the be obtained from 541 https://alkesgroup.broadinstitute.org/LDSCORE/. BLASTn was used as available from the NCBI: 542 https://blast.ncbi.nlm.nih.gov/Blast.cgi. Known reference and polymorphic NUMTs were 543 obtained from supplemental data as provided in published work (Calabrese et al., 2012; Dayama 544 et al., 2014; Li et al., 2012; Wei et al., 2022).

545

546 **CODE AVAILABILITY**

547 We release the full WDL pipelines for mtDNA analysis from whole genome sequencing data on 548 GitHub: (https://github.com/rahulg603/mtSwirl). We also provide the code we used to run the 549 pipeline on the UKB Research Analysis Platform, AoU, and Terra, consolidate all data, and 550 perform mtDNA sample and variant QC. See Methods and the README for more information on 551 how to use the pipeline. Several tools were used as part of mtSwirl, including GATK v4.2.6.0 (https://gatk.broadinstitute.org/), samtools v1.9 (https://github.com/samtools/samtools) and 552 553 bcftools v1.16 (https://github.com/samtools/bcftools), Haplochecker 0124

(https://github.com/genepi/haplocheck), R (r-project.org), Hail (hail.is), and UCSC kent LiftOver
 tools (genome-source.soe.ucsc.edu/kent.git).

556

557 We used several published tools and scripts to perform downstream analysis of the mtDNA 558 callset in this study. All data wrangling, statistical analysis, and figure generation was performed 559 using either Hail v0.2.98 (hail.is) or R v4.2.1 (r-project.org). Parallelization of tasks in UKB was (batch.hail.is) and in AoU 560 performed using Hail Batch using Cromwell v77 561 (cromwell.readthedocs.io). GWAS was performed in UKB using SAIGE v1.1.5 (saigegit.github.io). 562 For scaling of UKB GWAS, a custom modification of the GWAS pipeline from the Pan UKBB pan-563 ancestry GWAS was used (https://github.com/atgu/ukbb pan ancestry). GWAS was performed 564 in AoU using Hail. mtDNA PCA was performed in R using the irlba v2.3.5.1 package (https://cran.r-565 project.org/web/packages/irlba/index.html). Multinomial models were trained using the nnet 566 v7.3-17 package in R (https://cran.r-project.org/web/packages/nnet/index.html). Circos plots 567 were made using the circlize package v0.4.15 in R 568 (https://jokergoo.github.io/circlize_book/book/). For analysis of chrM:302 in single cell data, we 569 used BedTools v2.29.2 (bedtools.readthedocs.io). LD clumping was performed using Plink v1.90 (https://www.cog-genomics.org/plink/). Finemapping was performed using FINEMAP-inf and 570 571 SuSiE-inf (https://github.com/FinucaneLab/fine-mapping-inf). eQTL data was obtained from GTEx v8 (gtexportal.org) and the eQTL catalogue release 4 (https://www.ebi.ac.uk/eqtl/). For 572 replication analysis effect size comparisons, the deming pacakge v1.4 was used in R 573 574 (https://cran.r-project.org/web/packages/deming/index.html). Heritability estimates and 575 enrichment analyses performed were using stratified LD-score regression 576 (https://github.com/bulik/ldsc).

- 577
- 578

579 METHODS

580

581 **Overview of mtSwirl**:

582

583 Here we develop mtSwirl, a scalable pipeline for mitochondrial DNA copy number and variant 584 calling which makes calls relative to an internally generated per-sample consensus sequence before mapping all calls back to GRCh38. In addition to GRCh38 reference files and whole-585 586 genome sequencing (WGS) data, the mtSwirl pipeline takes as input nuclear genome reference 587 intervals that represent regions with high homology to the mtDNA (reference NUMTs). We 588 constructed a set of 385 putative NUMTs by using a BLAST-based inventory of reference NUMTs 589 published previously (Li et al., 2012), extending the boundaries of each interval by 500 bases, and 590 merging any overlapping intervals. Initial variant calls within the mtDNA and reference NUMT 591 regions are made from mapped WGS data using Mutect2 and HaplotypeCaller respectively (via 592 GATK v4.2.6.0), and haplogroup inference is performed via Haplogrep (Weissensteiner et al., 593 2016). Consensus sequences are subsequently constructed using homoplasmies (mtDNA) and 594 homozygous alternate (nucDNA) calls. Reads are realigned to the new consensus sequence and 595 variants are called on the mtDNA using Mutect2. To avoid the artificial coverage depression at 596 the ends of the mtDNA reference genome, we call variants in the control region after alignment 597 to a shifted mtDNA molecule. All variant calls and per-base coverage estimates are then returned 598 to GRCh38 coordinates and output from the pipeline. See **Supplementary note 1** for more details. 599 We release two versions of our pipeline on GitHub (https://github.com/rahulg603/mtSwirl): 600 mtSwirlSingle, a single-sample pipeline intended for use with Cromwell and on platforms with 601 high worker limits like Terra and the AllofUs Workbench, and mtSwirlMulti, a multi-sample 602 version which processes multiple samples serially per machine intended for use on platforms 603 with a smaller parallel worker limit such as the UKB Research Analysis Platform (RAP).

604

605 **Cohorts:** 606

607 UK Biobank (UKB)

608

The UK Biobank is a large prospective cohort study of ~500,000 individuals in the UK (Sudlow et al., 2015), ~200,000 of whom had whole genome sequencing performed at the time of this study. Samples were selected for the first round of WGS using a pseudorandom approach to ensure that included samples were representative of the full cohort. Sequencing data was generated using DNA extracted from buffy coat obtained from participants; more details have been reported previously (Halldorsson et al., 2022). All UKB data was accessed under application 31063 and mtDNA variant calling was performed on the UKB RAP.

- 616
- 617 AllofUs (AoU)
- 618

AllofUs is a large longitudinal cohort study based in the United States, with a central goal of enrolling a diverse cohort of participants providing electronic health record data over time, specimens for genetic analysis, survey responses, and standardized biometric measurements ("The 'All of Us' Research Program," 2019). At the time of this study, 98,590 individuals had 623 completed whole genome sequencing on samples obtained from whole blood. DNA extraction 624 was completed at the Mayo Clinic, and sequencing was performed at three sequencing centers 625 (Baylor College of Medicine, Broad Institute, and University of Washington) using harmonized 626 protocols. Post-sequencing variant and sample quality control was performed by the AllofUs Data 627 and Research Center (DRC). All mtDNA analyses were performed using the AllofUs Researcher 628 Workbench in the Controlled Tier v6 workspace: "Genetic determinants of mitochondrial DNA 629 phenotypes" using data from the Q2 2022 release. See 630 https://support.researchallofus.org/hc/en-631 us/article attachments/7237425684244/All Of Us Q2 2022 Release Genomic Quality Repo 632 rt.pdf for more details on genomics QC and pre-processing.

633

634 gnomAD v3.1 subset

635

636 gnomAD v3.1 is a database aggregating whole genome sequencing data from 76,156 samples 637 from several experiments and projects around the world, as part of which an mtDNA variant 638 callset was recently produced (Laricchia et al., 2022). Samples were sourced from several study 639 designs including case-control studies for common diseases, population-based cohorts, and 640 observational studies. Individuals with inborn severe pediatric disease were excluded. Most data 641 are sourced from sequencing performed on either blood samples extracted using study-specific 642 methodologies or from cell lines (Laricchia et al., 2022). We made use of a subset of the gnomAD 643 v3.1 samples to prototype our pipeline (mtSwirl) and compare its performance to previous 644 mtDNA copy number and variant calls ("Vanilla"). We excluded samples with very high mtDNA 645 copy number as done previously (Laricchia et al., 2022) as these are likely cell line samples and 646 not from whole blood; we used a more stringent threshold of 350 as we wanted to maximally 647 enrich for whole blood samples for this trial. We also removed samples with mtCN < 50 due to 648 elevated NUMT contamination in these samples (Laricchia et al., 2022, Supplementary figure 649 7C). We selected ~6300 samples from gnomAD v3.1 to maximize inclusion of diverse haplogroups 650 including those underrepresented in UK Biobank (Supplementary figure 2A). We specifically 651 supplemented samples belonging to the L haplogroups and enforced a cap on the number of 652 samples assigned to either NFE (Non-Finnish European) or FIN (Finnish). For other larger 653 haplogroups we performed random subsampling proportional to the original composition of the 654 gnomAD dataset to achieve our final sample size. All analyses were performed using Terra (Terra, 655 n.d.).

656

657 **Computing mean nuclear DNA coverage in UKB:**

658

As mean nuclear DNA coverage was not available in UK Biobank, we used samtools v1.9 idxstats (Danecek et al., 2021), samtools flagstat, and GATK v4.2.6.0 CollectQualityYieldMetrics as part of the mtSwirlMulti pipeline to efficiently and economically estimate mean coverage on the nuclear DNA. idxstats-based counts of total mapped reads were computed over autosomes with the subsequent formula applied to get average nuclear DNA coverage after removing contributions from duplicate reads:

665

666	mean coverage (total manned reads – sinaletons – reads w/ discordant mate – dunlicates) * read lenath
667	=(containing point of all of the string
668 669 670	Computing mtDNA copy number:
670 671 672	Across all cohorts we use the following formula to compute mtDNA copy number:
673 674	2 * mean or median mtDNA coverage/ mean nucDNA coverage
675 676	We default to use of mean mtDNA coverage for main mtCN-related analyses.
677 678	Post-calling mtDNA phenotype QC:
679 680 681 682 683	To integrate our variant calls and perform sample and variant QC, we extended a previously developed pipeline (Laricchia et al., 2022). Single-sample VCFs emitted from mtSwirl were merged into a single Hail MatrixTable (v0.2.98; (Hail Team, n.d.)) upon which all downstream steps were conducted.
683 684 685 686 687 688 689 690 691 691 692 693 694 605	For sample QC, any samples showing homoplasmic variant overlap (see Supplementary note 1) were removed. We observed a significant elevation in heteroplasmic SNV calls among samples with mtCN below 50, with a stabilization of heteroplasmic calls above 50 mtDNA copies per cell (Supplementary figure 7C), highly suggestive of elevated NUMT contamination in the low copy number samples. Thus, to avoid contamination of our results, all samples with mtCN < 50 were removed. Finally, all samples with evidence of contamination > 2% were removed, as estimated by either (1) mtDNA contamination via Haplocheck 0124 (Weissensteiner et al., 2021) in mtSwirl, (2) nucDNA contamination, or (3) the presence of multiple haplogroup-defining variants at abnormally low allele fraction. Given the small count of samples processed in 2006 and abnormally elevated mtDNA copy number estimates in these samples (Supplementary figure 3E), we excluded these samples from all UKB analyses.
695 696 697 698 699 700 701 702 703 704 705 706	For variant QC, (1) variants with a very low heteroplasmy (< 0.01) were called as reference with a heteroplasmy of 0, (2) variants with heteroplasmy below 0.05 were flagged and removed as these are at high risk of being enriched for NUMT-derived signals, and (3) all variant calls flagged by Mutect2 were removed. For all sites, a minimum coverage threshold of 100 was used to distinguish between homoplasmic reference calls and sites without variant calls due to low variant-calling confidence as done previously (Laricchia et al., 2022). mtDNA variants were annotated using the Variant Effect Predictor (VEP) v101 (McLaren et al., 2016) and dbSNP v151 (Sherry et al., 1999). Variants with at least 0.1% of samples passing filters showing a heteroplasmy between 0 and 0.5 were annotated as "common low heteroplasmy". Variant calls failing QC were coded with a missing heteroplasmy.
707	For mtCN, we remove the samples identified during variant callset sample QC showing signs of

708 contamination, abnormal overlapping homoplasmy calls, or which were processed in 2006. Since

we expect mtDNA-wide coverage measures, such as mtCN, to be robust to NUMTs, we do notenforce hard cutoffs on mtCN measurements.

711

712 Construction of mtDNA heteroplasmy phenotypes:

713

714 We defined our set of common heteroplasmies in UKB as "common low heteroplasmy" variants 715 (Methods) which are present as heteroplasmies in at least 500 individuals, resulting in 39 716 variants. We produced two main sets of phenotypes: (1) a "case-only" dataset consisting of 717 heteroplasmy values for these variants where any individuals without the variant detected were 718 coded as missing and (2) as "case-control" dataset where cases consisted of those with any 719 detectable heteroplasmy and controls consisted of those with the variant not detected. In both 720 phenotype schemes, samples identified as homoplasmic for each variant were always coded as 721 missing. For the case-control dataset, only samples which could be accurately inferred as 722 reference for each variant were labeled as controls - specifically, the sample was coded as 723 missing for a variant if it had a coverage < 100 at the site or showed the variant call as QC-fail 724 (Methods).

725

For sensitivity analyses, we produced several additional case-only heteroplasmy datasets: (1) where any variant calls supported by an alternate allele depth (AD alt) of less than the mean nuclear DNA coverage of the sample were made missing; (2) where heteroplasmy estimates were corrected for the depth of mtDNA coverage at the variant site after realignment; and (3) where length heteroplasmy estimates at chrM:302 were corrected for median coverage at CSBII. All corrections were performed by obtaining residuals from the linear regression of the heteroplasmy onto the covariate for each variant across all samples prior to genetic analysis.

733

734 mtDNA phenotype covariate correction approach:

735

736 We investigated time of day of blood draw, fasting time, assessment date, and assessment center 737 as technical covariates for mtDNA traits. As draw time and assessment date are continuous, we 738 used natural splines in the correction model to flexibly model nonlinear relationships between 739 these covariates and the mtDNA phenotype. We used knots placed roughly seasonally to model 740 seasonal variation in mtDNA phenotypes – these corresponded to 3-month increments starting 741 on July 1st 2007 and ending on July 1st 2010. For draw time, we used a natural spline basis with 5 742 degrees of freedom. Assessment month and assessment center were modeled as indicator 743 variables. Fasting times were provided in increments of 1 hour and thus were modeled as 744 indicator variables; fasting times of > 18 hours were labeled as 18 and fasting times of 0 were 745 labeled as 1. All terms were included in a joint model for correction.

746

We also investigated the relationship between mtDNA phenotypes and blood cell type percentages and mean blood cell volumes. We selected all non-redundant traits available: white blood cell leukocyte count, haematocrit percentage, platelet crit, monocyte percentage, neutrophil percentage, eosinophil percentage, basophil percentage, reticulocyte percentage, high light scatter reticulocyte percentage, immature reticulocyte fraction, mean corpuscular volume, mean reticulocyte volume, mean sphered cell volume, mean platelet thrombocyte

753 volume. We did not include nucleated red blood cell percentage as only ~1% of the entire UKB 754 cohort has non-zero values for this measure, and we excluded lymphocyte percentage given 755 collinearity with neutrophil percentage (r = 0.92) and the sum-to-1 property of the white blood 756 cell (WBC) differential measurements. To avoid excess leverage from outlying blood cell 757 measurements, we removed any blood measurements with a Z-score > 4. All terms were included 758 in a joint model for correction. 759 760 For both the technical covariate and blood cell type models, F-test p-values were obtained for 761 each of the 40 mtDNA phenotypes (39 case-only heteroplasmies and mtCN). For any phenotypes 762 which showed F-test p-values < 0.05/40 (Bonferroni corrected), we produced corrected versions 763 of the phenotype by obtaining the residuals from the regression of the mtDNA phenotype onto 764 covariates of interest prior to genetic analysis. For mtDNA copy number, adjustments were 765 performed with log(mtCN) as the response variable. For heteroplasmy estimates, adjustments 766 were performed with case-only heteroplasmies as the response variable. The specific corrections 767 implemented were: 768 769 $\log mtCN \sim ns(blood draw time, 5) + assessment center + fasting time$ 770 + ns(assessment date, SEASONAL KNOTS) + month of assessment 771 + blood cell variables 772 As sensitivity analyses for case-only heteroplasmy phenotypes, residuals from the following 773 774 models were produced: 775 776 $chrM: 567: A, ACCCCCC \sim ns(blood draw time, 5) + assessment center + fasting time$ + ns(assessment date, SEASONAL KNOTS) + month of assessment 777 778 779 (*chrM*: 16093: *T*, *C*; *chrM*: 16182: *A*, *ACC*; *chrM*: 16183: *A*, *AC*) ~ *blood cell variables* 780 781 For each response variable, residuals were generated using residuals(lm(model)) as 782 implemented in R v4.2.1. In all visualizations of corrected variables (e.g., mtCN_{corr}), we rescale the residualized variable by adding the pre-corrected mean. In the case of mtCN_{corr}, we rescale 783 784 the residualized variable and then exponentiate the same to return corrected values back to an 785 absolute scale. See Supplementary note 2 and 3 for more details. 786 787 mtDNA PCA and predictive power for mtDNA haplogroups: 788 789 To construct a high-quality variant genotype matrix for PCA, we obtained the set of homoplasmic 790 variants (heteroplasmy \geq 0.95) passing QC identified at a MAF \geq 0.001 in UKB. Any samples 791 with a QC-pass homoplasmy detected were coded as 1 for each respective variant; all others 792 were coded as 0. This binary genotype matrix was subsequently filtered to the set of unrelated 793 samples upon which we computed the first 50 principal components after centering and scaling 794 using the efficient truncated singular value decomposition algorithm implemented in the irlba 795 v2.3.5.1 package in R. Related samples were projected onto these PCs to produce a set of mtDNA-796 PC coordinates for each sample. The set of related samples were defined previously in the Pan

797 UKBB project (*Pan UKBB Initiative*, 2022). In brief, PC-relate was used as implemented in Hail
798 within each assigned genetic ancestry group in UKB and the maximal set of unrelated samples
799 were identified via the maximal independent set algorithm implemented in Hail.

800

801 To assess the goodness of fit of mtDNA PCs for the prediction of top-level mtDNA haplogroups, 802 we fit a multinomial model with top-level haplogroup as the response variable and the first 30 803 mtDNA PCs as explanatory variables as implemented in the nnet v7.3-17 package in R (Venables 804 & Ripley, 2002). We only included samples belonging to haplogroups with at least 30 samples in 805 UKB. For assessment of the predictive power of mtDNA PCs for "level 2" haplogroups, we fit 806 multinomial models using a similar approach within each top-level haplogroup, with "level 2" 807 haplogroups as the response variable. In all cases, a null model was fit in parallel with the same 808 response variable with only an intercept term. We computed McFadden's pseudo-R² for each 809 model via the following formula:

- 810
- 811

$$pseudoR^2 = 1 - \frac{\log likelihood}{null model \log likelihood}$$

812

813Correlations between mtCN, mtCNcorr, blood cell composition, heteroplasmies, and disease814phenotypes

815

816 We obtained common disease diagnoses from UKB via a previously curated set of phecodes and 817 ICD10 codes corresponding to major common diseases (Pan UKBB Initiative, 2022) along with 818 demographic variables (age, sex) and blood cell composition phenotypes (Methods). We obtained mtCN_{raw}, mtCN_{corr}, common (N > 500) case-only heteroplasmies (Methods), and three 819 820 major blood cell composition traits (platelet crit, monocyte count, and neutrophil count) and 821 performed z-score transformation for each. To test for associations with disease phenotypes, we 822 used a logistic regression model via the glm function in R, including age, sex, age², age²*sex, 823 age*sex, top-level haplogroup, and genetic ancestry group assignment as covariates:

824

827

825 disease phenotype ~ trait + age + sex + age^2 + age^2 * sex + age * sex + pop826 + top level haplogroup

We included haplogroups with at least 30 individuals represented in UKB. Odds ratios were obtained as exp (β_{trait}), and the 95% CI was obtained as exp ($\beta_{trait} \pm 1.96 * SE_{trait}$).

830

831 Derivation of mtDNA coverage discrepancy phenotypes:

We obtained mtDNA intervals corresponding to the 7s DNA, heavy strand origin, CSBII, CSBII, and the light strand promoter (LSP) (Falah et al., 2017; Tan et al., 2016; Xuan et al., 2006). We computed per-individual median mtDNA coverages within the regions corresponding to the first third of the 7s DNA ("7s DNA"), the region between CSBII and the heavy strand origin ("7s DNA primer"), and the region between CSB III and the LSP ("7s RNA primer"). To generate coverage discrepancy phenotypes, we regressed DNA primer coverage onto either 7s DNA coverage or 7s RNA primer coverage. To avoid coverage discrepancies attributable to inherited mtDNA variation 840 841

at least 30 samples as well as their interactions with 7s DNA or 7s RNA primer coverage. The 842 residuals from the following model were used as the coverage discrepancy phenotype for GWAS:

- 843
- 844 845

7s DNA primer coverage \sim (7s RNA primer or 7s DNA coverage) + haplogroup + (7s RNA primer or 7s DNA coverage) * haplogroup

within the regions of interest, we included indicator variables for all top-level haplogroups with

846

847 **Relatedness analyses in UKB:**

848

849 Relatedness was computed and sibling-sibling and parent-offspring pairs were inferred as 850 previously described in UKB (Karczewski et al., 2022). For the assessment of transmission of all 851 QC-pass mtDNA variants, we restricted to only variants found in 5 or more samples.

852

853 Determination of chrM:302 length heteroplasmy composition:

854

855 To construct length heteroplasmy profiles, we obtained all post-QC variant calls made at position chrM:302. We defined a "reference" call at chrM:302 for each sample as 1-856 857 sum(heteroplasmy of any allele at chrM: 302). All samples without variant calls at 858 chrM:302 were assigned a reference fraction of 1, with samples with a depth of < 100 at chrM:302 859 (after local re-alignment during variant calling) excluded. For each sample, we combined all 860 heteroplasmies from calls other than reference, chrM:302:A,AC, chrM:302:A,ACC, and 861 chrM:302:A,ACCC into an "Other" category. Any calls with a missing value for a chrM:302 allele 862 were imputed as a heteroplasmy of 0 for the purposes of visualizations and analyses. 863

864 Associations between pathogenic variant carrier status and continuous phenotypes in UKB: 865

866 We obtained continuous phenotypes available in UKB corresponding to classic symptoms of MELAS – diabetes-like symptoms (elevated triglycerides (ID 30870), elevated hemoglobin A1c (ID 867 868 30750)) and hearing impairment (via the speech-reception-threshold estimate (IDs 20019 and 869 20021)) – as well as the results from the visual acuity test for analysis of known pathogenic 870 variants for Leber's hereditary optic neuropathy (logMAR from visual acuity test (IDs 5201 and 871 5208)). All obtained phenotypes were filtered to samples with available mtDNA variant calls and 872 corrections were applied for age, sex, age², age²*sex, age*sex, and genetic ancestry group 873 assignment by obtaining residuals from the following linear regression model using 874 residuals(lm(model)) in R:

- 875
- 876 877

$$measurement \sim age + sex + age^2 + age^2 * sex + age * sex + pop$$

878 As blood biomarkers tend to have log-normal distributions, corrections were applied after log 879 transformation of HbA1c and triglyceride levels. Post-correction, all measurements were 880 returned to their original scale by adding the pre-correction dataset-wide means for each 881 measurement modality. Final estimates for the speech-recognition-threshold and vision logMAR 882 were generated by averaging measurements for the left and right ear and eye respectively.

883

Carriers of known pathogenic mtDNA variants were defined as individuals carrying the variant post-QC at any fraction. We defined a set of controls as individuals with none of the ten known pathogenic mtDNA variants tested. Only samples which could be accurately inferred as reference for all ten variants were labeled as controls – the sample was excluded if, for any of the ten variants, it had a coverage of below 100 at the site or showed a QC-fail variant call (**Methods**).

889

Comparisons between residual phenotype values among variant carriers versus global controls were performed only for variant-phenotype pairs with more than 10 defined phenotype values among variant carriers. P-values were obtained by performing a two-sample t-test between phenotype values among variant carriers and the set of global controls, and q-values were obtained by applying the Benjamini-Hochberg procedure.

895

897

896 Creation of mutational spectrum categories:

898 Heteroplasmic SNV mutation types in AllofUs were constructed using the set of QC-pass 899 heteroplasmic SNVs. For each SNV type, the set of individuals without any heteroplasmic variants 900 was identified as those with no QC-pass variant call of that type; these individuals were included 901 as zeros in estimates of the mean SNV count of each type.

- 903 chrM:302 length heteroplasmy inference in single cells:
- 904

902

905 We used the BedTools (Quinlan & Hall, 2010) intersect tool (v2.29.2) to identify read alignments 906 completely spanning the chrM:300-318 locus in the mtscATAC-seq data from Walker et al., 2020, 907 obtained with Massachusetts General Hospital IRB approval under protocol #2016P001517. We 908 then iterated over these reads and classified their chrM:302 length variant by extracting the poly-909 C/G tracts using a regular expression, 'AA(CCC+[CT]CC+)GC', anchored on the two constant bp on 910 either side of the variant region to detect the canonical variant structure of two poly-C/G tracts 911 with or without a single intervening A/T. Alleles in matching reads were classified based on the 912 length of their poly-C/G tracts, while alleles in the reads that did not match the regular expression 913 were classified as NA. Next, we filtered out any reads with cell barcodes that were not in the 914 published list of cell calls, and further restricted our analysis to only the cells with at least 20 915 reads at the chrM:300-318 locus. For each of these high coverage cells, we calculated the fraction 916 of reads showing each of the top three most common length variants (G_6AG_8 , G_6AG_9 , and G_6AG_{10}) 917 and aggregated any other detected alleles into the remainder (other) for display as a stacked bar 918 plot. We also estimated bulk heteroplasmy by summing the allele counts from the high coverage 919 cells and re-calculating the fractions for the top three length variants, again with all other alleles 920 being aggregated into the remainder "other" category.

921

922 UKB GWAS approach:

923

All GWAS was performed in UKB using approaches as performed in the Pan UKBB initiative (*Pan UKBB Initiative*, 2022). In brief, ancestry assignment was performed by projecting UKB samples into genotype PC-space constructed from reference samples from 1000 Genomes (1KG) phase 3 and the Human Genome Diversity Project (HGDP) and subsequently using a random forest

928 classifier to assign continental labels trained on the 1KG+HGDP reference data. Within each 929 ancestry group, PCA was performed among unrelated samples with related samples projected 930 onto this PC-space. Further sample QC was performed excluding samples as described as part of 931 the Pan UKBB initiative (Pan UKBB Initiative, 2022), including removal of ancestry outliers using 932 a centroid-based metric, individuals with high genotype missingness, sex discordance, and sex 933 chromosome aneuploidies. Variant QC was also performed on UKB-provided imputed v3 variants 934 as part of the Pan UKBB initiative (Pan UKBB Initiative, 2022), including only those with INFO 935 scores > 0.8 on autosomes and the X-chromosome. Association tests were performed only on 936 variants with a minor allele count (MAC) > 20.

937

For GWAS, SAIGE v1.1.5 (Zhou et al., 2018) was used to perform association tests within each assigned ancestry group using the first 10 per-population PCs, age, age*sex, age², and age²*sex as covariates (referred to as "baseline"). Ancestry groups were only included if at least 50 individuals had the phenotype defined. The use of the SAIGE GRM-based approach allowed for the inclusion of related samples in the GWAS, and we enabled leave-one-chromosome-out fitting in all steps. For all continuous phenotype GWAS (case-only mtDNA heteroplasmy traits and mtCN), phenotypes were inverse rank normalized prior to genetic analysis.

945

946 For all main mtDNA heteroplasmy analyses, top-level mtDNA haplogroup was included as an 947 additional set of covariates in the GWAS model as a set of 24 indicator variables with haplogroup 948 A as reference. Any samples belonging to top-level haplogroups with fewer than 30 samples 949 represented were excluded. The same GWAS model was used for sensitivity analysis of case-only 950 heteroplasmies after removing calls with AD alt < mean nucDNA coverage, after correction for 951 local variant coverage, after correction for CSBII coverage, and after correction for technical or 952 blood trait covariates (Methods). For the main mtCN analyses, we used only the baseline 953 covariates to perform genetic associations with mtCN_{raw} and mtCN_{corr}.

954

We performed two additional sensitivity analyses for case-only heteroplasmy GWAS: (1) inclusion
of 30 mtDNA PCs as covariates in the GWAS model instead of top-level haplogroup for 7 variants
which showed relatively high heterogeneity across level 2 haplogroups, and (2) inclusion of mtCN
as a covariate in the GWAS model for all case-only heteroplasmies in addition to top-level
haplogroup. We also tested the effects of including top-level haplogroup indicator variables as
additional covariates in GWAS for mtCN_{raw} and mtCN_{corr}.

961

962 AllofUs GWAS approach:

963

We performed GWAS in AllofUs as replication for our main case-only heteroplasmy analyses in
UKB. Ancestry inference was performed upstream by the AllofUs Data and Research Center
(DRC). In brief, AoU samples were projected into the PCA space of genotypes from chromosomes
20 and 21 from HGDP and 1KG, and a random forest classifier trained to identify ancestry labels
in 1KG+HGDP was used to assign AoU samples continental ancestry labels.

969

970 We performed sample and variant QC after WGS variant calls were imported into Hail. Multi-971 allelic sites were split and sites with very low pre-computed AF were removed (MAF > 0.0001 972 retained). For sample QC, samples flagged by the DRC as population outliers for several metrics 973 or identified as related by the DRC were excluded. For variant QC, we removed any variants 974 filtered by the DRC, which occurred in brief because of no high-quality genotypes for the variant 975 (defined as GQ >= 20, DP >= 10, AB >= 0.2 for heterozygotes), excess heterozygotes, or a low 976 quality score for the variant. We further removed any variants not in Hardy-Weinberg equilibrium 977 (one-sided p <= 1e-10) and variants with a call rate <= 0.95. Finally, we removed any variants with 978 MAC < 20 in each assigned an east to group

- 978 MAC < 20 in each assigned ancestry group.
- 979

980 We next extracted covariates relevant for our GWAS model. We used a SQL guery to obtain date 981 of birth in the controlled data repository and used the provided QC flat files to obtain sex assigned 982 at birth. As date of sample collection was not provided, approximate age was constructed for all 983 analyses by subtracting the year of birth from the year 2021. To address residual stratification 984 within assigned ancestry groups, we produced PCs within each ancestry group using a very similar 985 approach as used in UKB (Methods) as we found that the provided PCs did not appropriately 986 handle stratification among positive control phenotypes like height, blood glucose, diastolic 987 blood pressure, and systolic blood pressure (Supplementary note 4). We included 20 988 recomputed PCs, in addition to approximate age, age², age^{*}sex, and age²*sex as covariates in 989 the final GWAS model. We did not perform genetic analysis for the MID group as less than 400 990 samples with available WGS data were assigned MID.

991

992 We used Hail with the hl.linear regression rows() method to perform GWAS after 993 all QC. As described in Methods, we performed genetic analysis for all QC-pass case-only mtDNA 994 heteroplasmies with homoplasmic calls set to missing. As this analysis is intended for replication, 995 we included any variants found in 300 or more samples across any ancestry group, resulting in 996 41 variants for genetic analysis. Of these, 36 were also analyzed in UKB; 3 UKB variants were not 997 sufficiently common in AoU for genetic analysis. As in UKB, for the analysis of case-only mtDNA 998 heteroplasmies, top-level mtDNA haplogroup was included as covariates in the GWAS model as 999 a set of 27 indicator variables in addition to age, sex, and PC covariates. Samples belonging to 1000 top-level haplogroups with fewer than 30 samples in AoU were excluded. All case-only mtDNA 1001 heteroplasmy phenotypes were inverse rank normalized prior to analysis.

1002

1003See the AllofUs genotype quality report for more information on upstream genotype data and1004sampleQC, ancestry inference, and relatedness inference1005(https://support.researchallofus.org/hc/en-

1006 us/article_attachments/7237425684244/All_Of_Us_Q2_2022_Release_Genomic_Quality_Repo 1007 rt.pdf).

1008

1009 Heritability estimation and enrichment analyses for mtCN:

1010

Stratified linkage disequilibrium score regression (S-LDSC, Finucane et al., 2015) was used for heritability estimation and enrichment analyses for mtDNA copy number in UKB as performed previously (Gupta et al., 2021). In brief, we analyzed EUR summary statistics in UKB, restricting variants to those in HapMap3 (HM3). We estimated overall SNP-heritability controlling for 97 annotations corresponding to coding regions, enhancer regions, minor allele frequency bins, and 1016 others (Gazal et al., 2017, referred to as baselineLD v2.2). For enrichment analyses, we obtained 1017 gene-sets corresponding to (1) the top 10% of genes specifically expressed in major tissues from 1018 GTEx (Finucane et al., 2018) and (2) genes producing protein products that localize to each major 1019 organelle with high confidence using COMPARTMENTS (Binder et al., 2014). Variants were 1020 mapped to each gene with a 100kb symmetric window and LD scores for each gene-set 1021 annotation were computed using the 1000G EUR reference panel 1022 (https://alkesgroup.broadinstitute.org/LDSCORE/). Heritability enrichment for all gene-sets was 1023 tested using S-LDSC atop the baseline v1.1 model, controlling for 53 annotations including coding 1024 regions and 5' and 3' UTRs (Finucane et al., 2015).

1025

1027

1026 **Cross-ancestry meta-analysis in UKB and AllofUs:**

1028 We conducted a fixed-effect meta-analysis across ancestries in each cohort (UKB and AoU) based 1029 on inverse-variance weighted betas and standard errors (de Bakker et al., 2008). For each 1030 ancestry, we excluded low-confidence variants defined as MAC <= 20 in either biobank. We 1031 computed effect size heterogeneity P-values across ancestries using Cochran's Q-test (Cochran, 1032 1954). All computation was done using Hail v0.2.

1033

All visualizations of main GWAS (e.g., mtCN, coverage discrepancy traits, heteroplasmy traits) are
of cross-ancestry meta-analyses after restriction to the set of "high quality" variants as defined
previously (*Pan UKBB Initiative*, 2022).

- 1037
- 1038 Identification of LD-independent lead SNPs and locus definitions:
- 1039

1040 Clumping was performed using Plink v1.90 (Purcell et al., 2007) in Hail Batch for GWAS results 1041 obtained in UK Biobank after filtering to high quality variants. We used significance thresholds of 1042 1 for both the index and clumped SNPs, set the LD threshold for clumping at 0.1, and set the 1043 distance threshold at 500kb. We used single ancestry and multi-ancestry LD reference panels 1044 corresponding to the ancestry groups included in the final multi-ancestry meta-analyses for each 1045 mtDNA phenotype as well as for blood cell traits. Reference panels were constructed by randomly 1046 sampling 5000 individuals from all samples within any given set of ancestry groups in the UK 1047 Biobank. For the single-ancestry LD panels corresponding to ancestry groups with less than 5000 1048 individuals (EAS and MID), the full sample available for each ancestry group was used. More 1049 details on the LD reference panels can be found as part of the Pan UKBB project (Pan UKBB 1050 Initiative, 2022). Clumping output files from Plink were converted to Hail Tables and then 1051 combined into MatrixTables using the multi-way-zip-join method as implemented in Hail. 1052

- 1053 We defined distinct loci conservatively by starting with genome-wide significant LD-independent1054 lead SNPs and merging any SNPs within 2 Mb of one another.
- 1055
- 1056 **Replication of previous mtCN GWAS with our study:**
- 1057

1058 We performed a comparison of significant loci identified in a previous GWAS of mtCN in UKB 1059 (Longchamps et al., 2021) with our own by performing LD clumping on previously released summary statistics as described (**Methods**) using 1KG phase 3 EUR reference data for LD. We defined distinct loci as described (**Methods**), merging any SNPs within 2 Mb of one another, arriving at 96 loci previously identified. We defined a replicated locus with mtCN_{raw} or mtCN_{corr} as one where our GWAS showed a signal at $p < 5*10^{-5}$ or $5*10^{-8}$ within 2 Mb of the most significant variant identified in the previous study within each locus.

1065

1066 Bidirectional Mendelian randomization between UKB mtCN and neutrophil count:

1067

1068 GWAS effect sizes and LD-independent loci from the UKB cross-ancestry meta-analysis for raw 1069 mtCN and fully corrected mtCN were obtained. Summary statistics and LD-independent loci from 1070 GWAS among EUR for neutrophil count (ID 30140) were obtained from the Pan UKBB project 1071 (Pan UKBB Initiative, 2022). Sites for comparison were restricted to those passing variant QC as 1072 performed in UKB (Methods). For each mtCN phenotype, neutrophil count and mtCN GWAS 1073 effect sizes were obtained for all mtCN genome-wide significant variants, and vice-versa, mtCN 1074 and neutrophil count GWAS effect sizes were obtained for all neutrophil count genome-wide 1075 significant variants. We assessed the relationship between pre- and post-correction mtCN GWAS effect sizes and neutrophil count GWAS effect sizes via inverse-variance weighted linear 1076 regression using weights corresponding to $\frac{1}{SE(mtCN)^2} * \frac{1}{SE(neutrophil)^2}$, where effect size standard 1077 1078 errors were obtained from the respective GWAS.

1079

1080 Fine-mapping in UKB:

1081

To identify putative causal variants in associated loci, we conducted statistical fine-mapping of mtDNA traits in UKB using cross-ancestry meta-analysis summary statistics. While we previously showed that fine-mapping a meta-analysis is often miscalibrated due to heterogeneous characteristics of constituent cohorts (e.g., genotyping or imputation) (Kanai et al., 2022), a within-cohort cross-ancestry meta-analysis like the present study is a notable exception given no such heterogeneity systematically exists across ancestries.

1088

1089 We used FINEMAP-inf and SuSiE-inf which model infinitesimal effects (Cui et al., 2022), with 1090 cross-ancestry meta-analysis summary statistics (Methods) and a covariate-adjusted in-sample 1091 dosage LD matrix (Kanai et al., 2021). We defined fine-mapping regions based on a 3 Mb window 1092 around each lead variant and merged regions if they overlapped as described previously (Kanai 1093 et al., 2021). We excluded the major histocompatibility complex (MHC) region (chr 6: 25–36 Mb) 1094 from analysis due to extensive LD structure in the region. For each method, we allowed up to 10 1095 causal variants per region and derived posterior inclusion probabilities (PIP) of each variant using 1096 a uniform prior probability of causality. To achieve better calibration, we computed min(PIP) 1097 across the methods and derived up to 10 independent 95% credible sets (CS) from SuSiE-inf as 1098 described elsewhere (Kanai et al., 2021). All reported PIP are min(PIP) between the two methods. 1099

- 1100 Enrichment of functional categories among fine-mapped variants:
- 1101

1102 We computed functional enrichment of fine-mapped variants across the mtDNA traits in UKB. 1103 We first annotated each variant with seven functional categories (pLoF, missense, synonymous, 1104 5' UTR, 3' UTR, promoter, cis-regulatory element [CRE], and non-genic) as described previously 1105 (Kanai et al., 2021). We then estimated functional enrichment for each category as a relative risk 1106 (i.e., a ratio of proportion of variants) between being in an annotation and fine-mapped (PIP \leq 0.01 or PIP > 0.1). That is, a relative risk = (proportion of variants with PIP > 0.1 that are in the 1107 1108 annotation) / (proportion of variants with PIP ≤ 0.01 that are in the annotation). 95% confidence 1109 intervals are calculated using bootstrapping with 5,000 replicates. We note that, to increase 1110 statistical power, we combined pLoF/missense and 5'/3' UTR into single categories respectively 1111 and used a more lenient threshold (PIP > 0.1 vs. > 0.9) compared to our previous analysis (Kanai 1112 et al., 2021). 1113 1114 Gene- and variant-prioritization: 1115 1116 To nominate genes using GWAS results, we used the following approach to balance clarity with 1117 confidence in the gene assignment. 1118 1119 1. If the locus had a credible set, for each credible set (CS): 1120 a. Filter to variants in the credible set and retain variants from the CS that are either 1121 minimal PIP, coding, or have PIP > 0.7 1122 b. If the variant has PIP > 0.9 and is a coding variant for a gene, assign that gene to the CS 1123 1124 c. Otherwise assign genes within 3kb of the variant or, if no genes are within 3kb, 1125 assign the nearest gene to the CS 1126 2. If the locus had multiple credible sets and at least one had a variant with PIP > 0.1, we 1127 retained assignments only corresponding to variants with PIP > 0.11128 3. If the locus did not have a credible set, we assigned the gene with a boundary nearest to 1129 the most significant variant in the locus 1130 1131 If a variant is inside a gene body (but is non-coding), we consider that gene to be nearest. For 1132 case-only heteroplasmy GWAS, when the same locus was significant across multiple 1133 heteroplasmy phenotypes, we performed manual integration to arrive at a set of genes 1134 supported by the most compelling genetic evidence across variants for each locus. The SSBP1 1135 locus was particularly complex, so we assign SSBP1 (which harbors the max PIP variant) and 1136 provide visualization of the full locus (Supplementary figure 9K). We do not use fine-mapping 1137 evidence from variants with PIP > 0.1 that are not assigned to a credible set. All assignments were 1138 manually reviewed. In all GWAS visualizations, we label the strength of evidence supporting the 1139 gene assignment (e.g., if supported by moderate or high-PIP fine-mapped variants, coding 1140 variants). 1141 1142 **Colocalization with eQTLs:** 1143

1144 We conducted colocalization of fine-mapped variants of mtDNA phenotypes and *cis*-eQTL 1145 associations from GTEx v8 (Aguet et al., 2020) and eQTL catalogue release 4 (Kerimov et al., 2021) as described previously (Kanai et al., 2021). Briefly, we retrieved fine-mapping results of *cis*-eQTL associations that were fine-mapped using SuSiE (Wang et al., 2020) with covariate-adjusted insample dosage LD matrices (Kanai et al., 2021). We then computed a posterior inclusion probability of colocalization for a variant as a product of PIP for GWAS and for *cis*-eQTL (CLPP = PIP_{GWAS} × PIP_{*cis*-eQTL}) (Hormozdiari et al., 2016). When displaying colocalization across heteroplasmy traits, we indicate colocalization if we see colocalization PIP > 0.1 for the assigned gene and any variant in the credible set for any tissue and for any heteroplasmy trait.

1153

1154 **Replication of UKB heteroplasmy results in AllofUs:**

1155

To perform replication analysis in AllofUs, we used LD-independent lead SNPs from all case-only heteroplasmy GWAS originally performed in UKB (**Methods**). We filtered association statistics from AoU (**Methods**) to these lead variants and compared effect sizes when the variants were identified in AoU with MAC > 20. We used Deming regression implemented in the deming v1.4 package in R to assess the relationship between effect sizes for these lead SNPs in cross-ancestry meta-analyses in the two biobanks while accounting for standard errors in both (Deming, 1943; Zhou et al., 2022). We coded alleles such that effect sizes were always positive in UKB.

1163

1164 Assessment of LD with known polymorphic and reference NUMTs:

1165

1166 We collated an extensive database of polymorphic and reference NUMT intervals using BLAST, 1167 known reference NUMTs (Calabrese et al., 2012; Li et al., 2012), and published polymorphic 1168 NUMTs inferred using mate-pair mapping discordance (Dayama et al., 2014; Wei et al., 2022). To 1169 search for regions of homology to the mtDNA within the reference nucDNA, we used BLASTn with 1170 the GRCh37 reference genome with a word size of 11, an expect threshold of 0.05, short queries 1171 enabled, and default values for the other parameters. In total, we obtained 4,736 overlapping 1172 reference and polymorphic NUMT intervals. We constructed a 20kb window around each 1173 nucDNA NUMT region (10kb up, 10kb down) and then conservatively tested for LD $R^2 > 0.1$ 1174 between any SNP in the window and each lead variant at genome-wide significance for our UKB 1175 case-only heteroplasmy GWAS using in-sample genome-wide EUR LD matrices generated in UKB 1176 (Pan UKBB Initiative, 2022). All LD values used to examine individual loci in either biobank was 1177 computed in-sample – for example, in AoU we computed LD using the post-QC genotype 1178 MatrixTable (**Methods**) used for GWAS with the Hail function hl.ld matrix().

1179

1180 Multiple alignment of POLG2 protein sequence:

1181

POLG2 homologs were detected via best bi-directional BlastP hit (Expect < 1e-3) from human
and were aligned via MUSCLE (Edgar, 2004).

1184

1185 1186 REFERENCES 1187 1188 Agaronyan, K., Morozov, Y. I., Anikin, M., & Temiakov, D. (2015). Replication-transcription 1189 switch in human mitochondria. Science, 347(6221), 548-551. 1190 https://doi.org/10.1126/SCIENCE.AAA0986 1191 Aguet, F., Barbeira, A. N., Bonazzola, R., Brown, A., Castel, S. E., Jo, B., Kasela, S., Kim-Hellmuth, S., Liang, Y., Oliva, M., Flynn, E. D., Parsana, P., Fresard, L., Gamazon, E. R., Hamel, A. R., 1192 He, Y., Hormozdiari, F., Mohammadi, P., Muñoz-Aguirre, M., ... Volpi, S. (2020). The GTEx 1193 1194 Consortium atlas of genetic regulatory effects across human tissues. Science, 369(6509), 1195 1318–1330. https://doi.org/10.1126/SCIENCE.AAZ1776/SUPPL FILE/AAZ1776 TABLESS10-1196 S16.XLSX 1197 Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H. L., Coulson, A. R., Drouin, J., Eperon, I. 1198 C., Nierlich, D. P., Roe, B. A., Sanger, F., Schreier, P. H., Smith, A. J. H., Staden, R., & Young, 1199 I. G. (1981). Sequence and organization of the human mitochondrial genome. *Nature*, 1200 290(6), 338-346. 1201 Ashar, F. N., Zhang, Y., Longchamps, R. J., Lane, J., Moes, A., Grove, M. L., Mychaleckyj, J. C., 1202 Taylor, K. D., Coresh, J., Rotter, J. I., Boerwinkle, E., Pankratz, N., Guallar, E., & Arking, D. E. 1203 (2017). Association of mitochondrial DNA copy number with cardiovascular disease. JAMA 1204 Cardiology, 2(11), 1247–1255. https://doi.org/10.1001/jamacardio.2017.3683 1205 Aul, P., Idker, M. R., Ifai, A. R., Ynda, L., Ose, R., Ulie, J., Uring, E. B., & Ook, A. R. C. (2002). 1206 Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the 1207 Prediction of First Cardiovascular Events. Https://Doi.Org/10.1056/NEJMoa021993, 1208 347(20), 1557–1565. https://doi.org/10.1056/NEJMOA021993 1209 Battersby, B. J., Loredo-Osti, J. C., & Shoubridge, E. A. (2003). Nuclear genetic control of 1210 mitochondrial DNA segregation. Nature Genetics, 33(2), 183–186. 1211 https://doi.org/10.1038/ng1073 1212 Binder, J. X., Pletscher-Frankild, S., Tsafou, K., Stolte, C., O'Donoghue, S. I., Schneider, R., & 1213 Jensen, L. J. (2014). COMPARTMENTS: Unification and visualization of protein subcellular 1214 localization evidence. Database, 2014, 1–9. https://doi.org/10.1093/database/bau012 1215 Brown, M. D., Trounce, I. A., Jun, A. S., Allen, J. C., & Wallace, D. C. (2000). Functional analysis of 1216 lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 leber's 1217 hereditary optic neuropathy mitochondrial DNA mutation. Journal of Biological Chemistry, 1218 275(51), 39831-39836. https://doi.org/10.1074/jbc.M006476200 1219 Brown, W. M., George, M., & Wilson, A. C. (1979). Rapid evolution of animal mitochondrial 1220 DNA. Proceedings of the National Academy of Sciences, 76(4), 1967–1971. 1221 https://doi.org/10.1073/PNAS.76.4.1967 1222 Calabrese, F. M., Simone, D., & Attimonelli, M. (2012). Primates and mouse NumtS in the UCSC 1223 Genome Browser. BMC Bioinformatics, 13(SUPPL.4), 1–9. https://doi.org/10.1186/1471-1224 2105-13-S4-S15/FIGURES/5 1225 Cann, R. L., Stoneking, M., & Wilson, A. C. (1987). Mitochondrial DNA and human evolution. 1226 Nature, 325(6099), 31–36. https://doi.org/10.1038/325031A0 1227 Chong, M. R., Narula, S., Morton, R., Judge, C., Akhabir, L., Cawte, N., Pathan, N., Lali, R., 1228 Mohammadi-Shemirani, P., Shoamanesh, A., O'Donnell, M., Yusuf, S., Langhorne, P., & Par

- 1229 e, G. (2022). Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke
- 1230 Prognosis. *Neurology*, *98*(5), e470–e482.
- 1231 https://doi.org/10.1212/WNL.00000000013165
- Cochran, W. G. (1954). The Combination of Estimates from Different Experiments. *Biometrics*,
 10(1), 101. https://doi.org/10.2307/3001666
- Cui, R., Elzur, R. A., Kanai, M., Ulirsch, J. C., Weissbrod, O., Daly, M. J., Neale, B. M., Fan, Z., &
 Finucane, H. K. (2022). Improving fine-mapping by modeling infinitesimal effects. *BioRxiv*,
 2022.10.21.513123. https://doi.org/10.1101/2022.10.21.513123
- Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A.,
 Keane, T., McCarthy, S. A., Davies, R. M., & Li, H. (2021). Twelve years of SAMtools and
 BCFtools. *GigaScience*, *10*(2), 1–4. https://doi.org/10.1093/GIGASCIENCE/GIAB008
- Dayama, G., Emery, S. B., Kidd, J. M., & Mills, R. E. (2014). The genomic landscape of
 polymorphic human nuclear mitochondrial insertions. *Nucleic Acids Research*, 42(20),
 12640–12649. https://doi.org/10.1093/nar/gku1038
- de Bakker, P. I. W., Ferreira, M. A. R., Jia, X., Neale, B. M., Raychaudhuri, S., & Voight, B. F.
 (2008). Practical aspects of imputation-driven meta-analysis of genome-wide association
 studies. *Human Molecular Genetics*, *17*(R2), R122–R128.
- 1246 https://doi.org/10.1093/HMG/DDN288
- 1247 Deming, W. E. (1943). Statistical adjustment of data. In *Statistical adjustment of data*. Wiley.
- D'Erchia, A. M., Atlante, A., Gadaleta, G., Pavesi, G., Chiara, M., de Virgilio, C., Manzari, C.,
 Mastropasqua, F., Prazzoli, G. M., Picardi, E., Gissi, C., Horner, D., Reyes, A., Sbisà, E., Tullo,
 A., & Pesole, G. (2015). Tissue-specific mtDNA abundance from exome data and its
 correlation with mitochondrial transcription, mass and respiratory activity. *Mitochondrion*,
- 1252 20, 13–21. https://doi.org/10.1016/j.mito.2014.10.005
- Ding, J., Sidore, C., Butler, T. J., Wing, M. K., Qian, Y., Meirelles, O., Busonero, F., Tsoi, L. C.,
 Maschio, A., Angius, A., Kang, H. M., Nagaraja, R., Cucca, F., Abecasis, G. çR, & Schlessinger,
 D. (2015). Assessing Mitochondrial DNA Variation and Copy Number in Lymphocytes of
 ~2,000 Sardinians Using Tailored Sequencing Analysis Tools. *PLoS Genetics*, *11*(7), 1005306.
- 1257 https://doi.org/10.1371/JOURNAL.PGEN.1005306
- Edgar, R. C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high
 throughput. *Nucleic Acids Research*, 32(5), 1792–1797.
- 1260 https://doi.org/10.1093/NAR/GKH340
- 1261 Ekstrand, M. I., Falkenberg, M., Rantanen, A., Park, C. B., Gaspari, M., Hultenby, K., Rustin, P.,
 1262 Gustafsson, C. M., & Larsson, N. G. (2004). Mitochondrial transcription factor A regulates
 1263 mtDNA copy number in mammals. *Human Molecular Genetics*, *13*(9), 935–944.
 1264 https://doi.org/10.1093/hmg/ddh109
- Elliott, H. R., Samuels, D. C., Eden, J. A., Relton, C. L., & Chinnery, P. F. (2008). Pathogenic
 Mitochondrial DNA Mutations Are Common in the General Population. *American Journal*of Human Genetics, 83(2), 254–260. https://doi.org/10.1016/j.ajhg.2008.07.004
- Falah, M., Farhadi, M., Kamrava, S. K., Mahmoudian, S., Daneshi, A., Balali, M., Asghari, A., &
 Houshmand, M. (2017). Association of genetic variations in the mitochondrial DNA control
 region with presbycusis. *Clinical Interventions in Aging*, *12*, 459.
- 1270 region with presbytusis. Clinical interventions in Aging
- 1271 https://doi.org/10.2147/CIA.S123278

Falkenberg, M., & Gustafsson, C. M. (2020). Mammalian mitochondrial DNA replication and mechanisms of deletion formation. *Https://Doi.Org/10.1080/10409238.2020.1818684*,

1274 55(6), 509–524. https://doi.org/10.1080/10409238.2020.1818684

- Fazzini, F., Lamina, C., Raftopoulou, A., Koller, A., Fuchsberger, C., Pattaro, C., del Greco, F. M.,
 Döttelmayer, P., Fendt, L., Fritz, J., Meiselbach, H., Schönherr, S., Forer, L., Weissensteiner,
 H., Pramstaller, P. P., Eckardt, K. U., Hicks, A. A., & Kronenberg, F. (2021). Association of
- 1278 mitochondrial DNA copy number with metabolic syndrome and type 2 diabetes in 14 176 1279 individuals. *Journal of Internal Medicine*, *290*(1), 190–202.
- 1280 https://doi.org/10.1111/joim.13242
- Finucane, H. K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P. R., Anttila, V., Xu, H.,
 Zang, C., Farh, K., Ripke, S., Day, F. R., Purcell, S., Stahl, E., Lindstrom, S., Perry, J. R. B.,
 Okada, Y., Raychaudhuri, S., Daly, M. J., ... Price, A. L. (2015). Partitioning heritability by
 functional annotation using genome-wide association summary statistics. *Nature Genetics*,
- 1285 47(11), 1228–1235. https://doi.org/10.1038/ng.3404
- Finucane, H. K., Reshef, Y. A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., Loh, P.
 R., Lareau, C., Shoresh, N., Genovese, G., Saunders, A., Macosko, E., Pollack, S., Perry, J. R.
 B., Buenrostro, J. D., Bernstein, B. E., Raychaudhuri, S., McCarroll, S., ... Price, A. L. (2018).
 Heritability enrichment of specifically expressed genes identifies disease-relevant tissues
 and cell types. *Nature Genetics*, *50*(4), 621–629. https://doi.org/10.1038/s41588-0180081-4
- Frazier, A. E., Thorburn, D. R., & Compton, A. G. (2019). Mitochondrial energy generation
 disorders: Genes, mechanisms, and clues to pathology. *Journal of Biological Chemistry*,
 294(14), 5386–5395. https://doi.org/10.1074/jbc.R117.809194
- Gazal, S., Finucane, H. K., Furlotte, N. A., Loh, P. R., Palamara, P. F., Liu, X., Schoech, A., BulikSullivan, B., Neale, B. M., Gusev, A., & Price, A. L. (2017). Linkage disequilibrium-dependent
 architecture of human complex traits shows action of negative selection. *Nature Genetics*,
 49(10), 1421–1427. https://doi.org/10.1038/ng.3954
- Gitschlag, B. L., Kirby, C. S., Samuels, D. C., Gangula, R. D., Mallal, S. A., & Patel, M. R. (2016).
 Homeostatic Responses Regulate Selfish Mitochondrial Genome Dynamics in C. elegans. *Cell Metabolism*, 24(1), 91–103. https://doi.org/10.1016/j.cmet.2016.06.008
- Gopal, R. K., Calvo, S. E., Shih, A. R., Chaves, F. L., McGuone, D., Mick, E., Pierce, K. A., Li, Y.,
 Garofalo, A., van Allen, E. M., Clish, C. B., Oliva, E., & Mootha, V. K. (2018). Early loss of
 mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. *Proceedings of the National Academy of Sciences of the United States of America*, 115(27),
 E6283–E6290.
- 1307 https://doi.org/10.1073/PNAS.1711888115/SUPPL_FILE/PNAS.1711888115.SD05.XLSX
- 1308 Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P. M., Campbell,
- 1309 B., Donovan, S. E., Amin, S., Gigliotti, B. J., Grabarek, Z., Hess, J. M., Stewart, C., Braunstein,
- 1310 L. Z., Arndt, P. F., Mordecai, S., Shih, A. R., Chaves, F., ... McFadden, D. G. (2018).
- 1311 Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in
- 1312Hürthle Cell Carcinoma. Cancer Cell, 34(2), 242-255.e5.
- 1313 https://doi.org/10.1016/J.CCELL.2018.06.013

- Gupta, R., Karczewski, K. J., Howrigan, D., Neale, B. M., & Mootha, V. K. (2021). Human genetic
 analyses of organelles highlight the nucleus in age-related trait heritability. *ELife*, *10*,
 e68610. https://doi.org/10.7554/eLife.68610
- Hägg, S., Jylhävä, J., Wang, Y., Czene, K., & Grassmann, F. (2020). Deciphering the genetic and
 epidemiological landscape of mitochondrial DNA abundance. *Human Genetics*, *140*(6),
 849–861. https://doi.org/10.1007/s00439-020-02249-w
- 1320 Hail Team. (n.d.). *Hail 0.2*. Retrieved December 19, 2022, from https://github.com/hail-is/hail
- Halldorsson, B. v., Eggertsson, H. P., Moore, K. H. S., Hauswedell, H., Eiriksson, O., Ulfarsson, M.
 O., Palsson, G., Hardarson, M. T., Oddsson, A., Jensson, B. O., Kristmundsdottir, S.,
- Sigurpalsdottir, B. D., Stefansson, O. A., Beyter, D., Holley, G., Tragante, V., Gylfason, A.,
 Olason, P. I., Zink, F., ... Stefansson, K. (2022). The sequences of 150,119 genomes in the
 UK Biobank. *Nature 2022 607:7920, 607*(7920), 732–740. https://doi.org/10.1038/s41586 022-04965-x
- Holt, I. J., Harding, A. E., & Morgan-Hughes, J. A. (1988). Deletions of muscle mitochondrial DNA
 in patients with mitochondrial myopathies. *Nature*, *331*(6158), 717–719.
- 1329 https://doi.org/10.1038/331717a0
- Hormozdiari, F., van de Bunt, M., Segrè, A. v., Li, X., Joo, J. W. J., Bilow, M., Sul, J. H.,
 Sankararaman, S., Pasaniuc, B., & Eskin, E. (2016). Colocalization of GWAS and eQTL Signals
 Detects Target Genes. *American Journal of Human Genetics*, *99*(6), 1245–1260.
 https://doi.org/10.1016/j.ajhg.2016.10.003
- Hurtado-Roca, Y., Ledesma, M., Gonzalez-Lazaro, M., Moreno-Loshuertos, R., Fernandez-Silva,
 P., Enriquez, J. A., & Laclaustra, M. (2016). Adjusting MtDNA quantification in whole blood
 for peripheral blood platelet and leukocyte counts. *PLoS ONE*, *11*(10).
- 1337 https://doi.org/10.1371/journal.pone.0163770
- Kanai, M., Elzur, R., Zhou, W., Daly, M. J., Finucane, H. K., Zhou, W., Kanai, M., Wu, K.-H. H.,
 Rasheed, H., Tsuo, K., Hirbo, J. B., Wang, Y., Bhattacharya, A., Zhao, H., Namba, S., Surakka,
 I., Wolford, B. N., Io Faro, V., Lopera-Maya, E. A., ... Neale, B. M. (2022). Meta-analysis finemapping is often miscalibrated at single-variant resolution. *Cell Genomics*, 2(12), 100210.
 https://doi.org/10.1016/J.XGEN.2022.100210
- Kanai, M., Ulirsch, J. C., Karjalainen, J., Kurki, M., Karczewski, K. J., Fauman, E., Wang, Q. S.,
 Jacobs, H., Aguet, F., Ardlie, K. G., Kerimov, N., Alasoo, K., Benner, C., Ishigaki, K., Sakaue,
 S., Reilly, S., BioBank Japan Project, T., Kamatani, Y., Matsuda, K., ... Kanai mkanai, M.
 (2021). Insights from complex trait fine-mapping across diverse populations. *MedRxiv*,
- 1347 2021.09.03.21262975. https://doi.org/10.1101/2021.09.03.21262975
- Kang, E., Wu, J., Gutierrez, N. M., Koski, A., Tippner-Hedges, R., Agaronyan, K., Platero-Luengo,
 A., Martinez-Redondo, P., Ma, H., Lee, Y., Hayama, T., van Dyken, C., Wang, X., Luo, S.,
 Ahmed, R., Li, Y., Ji, D., Kayali, R., Cinnioglu, C., ... Mitalipov, S. (2016). Mitochondrial
 replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. *Nature*,
 540(7632), 270–275. https://doi.org/10.1038/nature20592
- 1353 Karczewski, K. J., Solomonson, M., Chao, K. R., Goodrich, J. K., Tiao, G., Lu, W., Riley-Gillis, B. M., 1354 Tsai, E. A., Kim, H. I., Zheng, X., Rahimov, F., Esmaeeli, S., Grundstad, A. J., Reppell, M.,
- 1354 Tsai, E. A., Kim, H. I., Zheng, X., Rahmov, F., Esmaeeli, S., Grundstad, A. J., Reppell, M., 1355 Waring, J., Jacob, H., Sexton, D., Bronson, P. G., Chen, X., ... Neale, B. M. (2022). Systematic
- 1356 single-variant and gene-based association testing of thousands of phenotypes in

- 1357 394,841 UK Biobank exomes. *Cell Genomics*, *2*(9), 100168.
- 1358 https://doi.org/10.1016/J.XGEN.2022.100168
- Kennedy, S. R., Salk, J. J., Schmitt, M. W., & Loeb, L. A. (2013). Ultra-Sensitive Sequencing
 Reveals an Age-Related Increase in Somatic Mitochondrial Mutations That Are Inconsistent
- 1361 with Oxidative Damage. *PLoS Genetics*, *9*(9).
- 1362 https://doi.org/10.1371/journal.pgen.1003794
- Kerimov, N., Hayhurst, J. D., Peikova, K., Manning, J. R., Walter, P., Kolberg, L., Samoviča, M.,
 Sakthivel, M. P., Kuzmin, I., Trevanion, S. J., Burdett, T., Jupp, S., Parkinson, H.,
- Papatheodorou, I., Yates, A. D., Zerbino, D. R., & Alasoo, K. (2021). A compendium of
 uniformly processed human gene expression and splicing quantitative trait loci. *Nature Genetics 2021 53:9, 53*(9), 1290–1299. https://doi.org/10.1038/s41588-021-00924-w
- Laricchia, K. M., Lake, N. J., Watts, N. A., Shand, M., Haessly, A., Gauthier, L., Benjamin, D.,
 Banks, E., Soto, J., Garimella, K., Emery, J., Aggregation, G., Consortium, D., Rehm, H. L.,
 Macarthur, D. G., Tiao, G., Lek, M., Mootha, V. K., & Calvo, S. E. (2022). Mitochondrial DNA
 variation across 56,434 individuals in gnomAD. *Genome Res.* https://bravo.sph.umich.edu
- 1371 Variation across 30,434 individuals in gromAD. Genome Res. https://bravo.spii.umicn.ed
 1372 Li, M., Schröder, R., Ni, S., Madea, B., & Stoneking, M. (2015). Extensive tissue-related and
 1373 allele-related mtDNA heteroplasmy suggests positive selection for somatic mutations.
- Proceedings of the National Academy of Sciences, 112(8), 2491–2496.
 https://doi.org/10.1073/pnas.1419651112
- Li, M., Schroeder, R., Ko, A., & Stoneking, M. (2012). Fidelity of capture-enrichment for mtDNA
 genome sequencing: Influence of NUMTs. *Nucleic Acids Research*, 40(18).
 https://doi.org/10.1093/nar/gks499
- Lim, S. E., Longley, M. J., & Copeland, W. C. (1999). The mitochondrial p55 accessory subunit of
 human DNA polymerase γ enhances DNA binding, promotes processive DNA synthesis, and
 confers N- ethylmaleimide resistance. *Journal of Biological Chemistry*, 274(53), 38197–
 38203. https://doi.org/10.1074/jbc.274.53.38197
- Lin, Y. F., Schulz, A. M., Pellegrino, M. W., Lu, Y., Shaham, S., & Haynes, C. M. (2016).
 Maintenance and propagation of a deleterious mitochondrial genome by the
 mitochondrial unfolded protein response. *Nature 2016 533:7603, 533*(7603), 416–419.
 https://doi.org/10.1038/nature17989
- Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S., & Hirschhorn, J. N. (2003). Meta-analysis
 of genetic association studies supports a contribution of common variants to susceptibility
 to common disease. *Nature Genetics 2003 33:2, 33*(2), 177–182.
- 1390 https://doi.org/10.1038/ng1071
- Longchamps, R. J., Yang, S. Y., Castellani, C. A., Shi, W., Lane, J., Grove, M. L., Bartz, T. M.,
 Sarnowski, C., Burrows, K., Guyatt, A. L., Gaunt, T. R., Kacprowski, T., Yang, J., de Jager, P.
 L., Yu, L., Bergman, A., Xia, R., Fornage, M., Feitosa, M. F., ... Arking, D. E. (2021). Genomewide analysis of mitochondrial DNA copy number reveals multiple loci implicated in
 nucleotide metabolism, platelet activation, and megakaryocyte proliferation. *BioRxiv*,
 2021.01.25.428086. https://doi.org/10.1101/2021.01.25.428086
- Longley, M. J., Clark, S., Man, C. Y. W., Hudson, G., Durham, S. E., Taylor, R. W., Nightingale, S.,
 Turnbull, D. M., Copeland, W. C., & Chinnery, P. F. (2006). Mutant POLG2 Disrupts DNA
 Polymerase γ Subunits and Causes Progressive External Ophthalmoplegia. *The American Journal of Human Genetics*, *78*(6), 1026–1034. https://doi.org/10.1086/504303

- Lynch, M., Butcher, D., Bürger, R., & Gabriel, W. (1993). The Mutational Meltdown in Asexual
 Populations. *Journal of Heredity*, *84*(5), 339–344.
- 1403 https://doi.org/10.1093/OXFORDJOURNALS.JHERED.A111354
- Marchington, D. R., Hartshorne, G. M., Barlow, D., & Poulton, J. (1997). Homopolymeric tract
 heteroplasmy in mtDNA from tissues and single oocytes: support for a genetic bottleneck.
 American Journal of Human Genetics, *60*(2), 408.
- 1407 /pmc/articles/PMC1712400/?report=abstract
- McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., &
 Cunningham, F. (2016). The Ensembl Variant Effect Predictor. *Genome Biology*, *17*(1), 1–
 14. https://doi.org/10.1186/S13059-016-0974-4/TABLES/8
- 1411 Nishino, I., Spinazzola, A., & Hirano, M. (1999). Thymidine Phosphorylase Gene Mutations in
 1412 MNGIE, a Human Mitochondrial Disorder. *Science*, 283(5402), 689–692.
- 1413 https://doi.org/10.1126/science.283.5402.689
- 1414 Pan UKBB Initiative. (2022). https://pan.ukbb.broadinstitute.org/
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar,
 P., de Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). PLINK: A Tool Set for WholeGenome Association and Population-Based Linkage Analyses. *American Journal of Human Genetics*, *81*(3), 559. https://doi.org/10.1086/519795
- Quinlan, A. R., & Hall, I. M. (2010). BEDTools: A flexible suite of utilities for comparing genomic
 features. *Bioinformatics*, *26*(6), 841–842. https://doi.org/10.1093/bioinformatics/btq033
- Rath, S., Sharma, R., Gupta, R., Ast, T., Chan, C., Durham, T. J., Goodman, R. P., Grabarek, Z.,
 Haas, M. E., Hung, W. H. W., Joshi, P. R., Jourdain, A. A., Kim, S. H., Kotrys, A. v, Lam, S. S.,
 Mccoy, J. G., Meisel, J. D., Miranda, M., Panda, A., ... Mootha, V. K. (2020). MitoCarta3.0:
- an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. *Nucleic Acids Research*, 1–7. https://doi.org/10.1093/nar/gkaa1011
- 1426 Ratnaike, T. E., Greene, D., Wei, W., Sanchis-Juan, A., Schon, K. R., van den Ameele, J.,
- Raymond, L., Horvath, R., Turro, E., & Chinnery, P. F. (2021). MitoPhen database: A human
 phenotype ontology-based approach to identify mitochondrial DNA diseases. *Nucleic Acids Research*, *49*(17), 9686–9695. https://doi.org/10.1093/nar/gkab726
- 1430 Rydzanicz, M., Cywińska, K., Wróbel, M., Pollak, A., Gawócki, W., Wojsyk-Banaszak, I.,
- 1431 Lechowicz, U., Mueller-Malesińska, M., Ołdak, M., Płoski, R., Skarzyński, H., Szyfter, K., &
- 1432 Szyfter, W. (2011). The contribution of the mitochondrial COI/tRNA Ser(UCN) gene
- 1433 mutations to non-syndromic and aminoglycoside-induced hearing loss in Polish patients.
- 1434 Molecular Genetics and Metabolism, 104(1–2), 153–159.
- 1435 https://doi.org/10.1016/j.ymgme.2011.05.004
- 1436 Sang, Y., Liu, J. Y., Wang, F. Y., Luo, X. Y., Chen, Z. Q., Zhuang, S. M., & Zhu, Y. (2022).
- 1437Mitochondrial micropeptide STMP1 promotes G1/S transition by enhancing mitochondrial1438complex IV activity. *Molecular Therapy*, 30(8), 2844–2855.
- 1439 https://doi.org/10.1016/J.YMTHE.2022.04.012
- Sharma, R., Reinstadler, B., Engelstad, K., Skinner, O. S., Stackowitz, E., Haller, R. G., Clish, C. B.,
 Pierce, K., Walker, M. A., Fryer, R., Oglesbee, D., Mao, X., Shungu, D. C., Khatri, A., Hirano,
 M., de Vivo, D. C., & Mootha, V. K. (2021). Circulating markers of NADH-reductive stress
 correlate with mitochondrial disease severity. *Journal of Clinical Investigation*, *131*(2), 1–
- 1444 16. https://doi.org/10.1172/JCI136055

- Sherry, S. T., Ward, M., & Sirotkin, K. (1999). dbSNP—Database for Single Nucleotide
 Polymorphisms and Other Classes of Minor Genetic Variation. *Genome Research*, 9(8),
 677–679. https://doi.org/10.1101/GR.9.8.677
- 1448Shoffner, J. M., Brown, M. D., Stugard, C., June, A. S., Pollock, S., Haas, R. H., Kaufman, A.,1449Koontz, D., Kim, Y., Graham, J. R., Smith, E., Dixon, J., & Wallace, D. C. (1995). Leber's
- 1450 hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point
- mutation. Annals of Neurology, 38(2), 163–169. https://doi.org/10.1002/ANA.410380207
 Stoneking, M. (2000). Hypervariable Sites in the mtDNA Control Region Are Mutational
- 1453 Hotspots. In *Am. J. Hum. Genet* (Vol. 67).
- Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green,
 J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T.,
 Peakman, T., & Collins, R. (2015). UK Biobank: An Open Access Resource for Identifying the
 Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Medicine*, *12*(3),
- 1458 1–10. https://doi.org/10.1371/journal.pmed.1001779
- Suomalainen, A., Kaukonen, J., Amati, P., Timonen, R., Haltia, M., Weissenbach, J., Zeviani, M.,
 Somer, H., & Peltonen, L. (1995). An autosomal locus predisposing to deletions of
 mitochondrial DNA. *Nature Genetics*, 9(2), 146–151. https://doi.org/10.1038/ng0295-146
- Tan, B. G., Wellesley, F. C., Savery, N. J., & Szczelkun, M. D. (2016). Length heterogeneity at
 conserved sequence block 2 in human mitochondrial DNA acts as a rheostat for RNA
 polymerase POLRMT activity. *Nucleic Acids Research*, 44(16), 7817–7829.
 https://doi.org/10.1093/nar/gkw648
- 1466 *Terra*. (n.d.). Retrieved November 4, 2022, from https://app.terra.bio/
- 1467The "All of Us" Research Program. (2019). New England Journal of Medicine, 381(7), 668–676.1468https://doi.org/10.1056/NEJMSR1809937/SUPPL_FILE/NEJMSR1809937_APPENDIX.PDF
- Thomas, W. K., & Wilson, A. C. (1991). Mode and tempo of molecular evolution in the
 nematode caenorhabditis: cytochrome oxidase II and calmodulin sequences. *Genetics*,
 128(2), 269–279. https://doi.org/10.1093/GENETICS/128.2.269
- 1472 Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E.,
- Bohlooly-Y, M., Gldlöf, S., Oldfors, A., Wibom, R., Törnell, J., Jacobs, H. T., & Larsson, N. G.
 (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature*, *429*(6990), 417–423. https://doi.org/10.1038/nature02517
- Uhler, J. P., Thörn, C., Nicholls, T. J., Matic, S., Milenkovic, D., Gustafsson, C. M., & Falkenberg,
 M. (2016). MGME1 processes flaps into ligatable nicks in concert with DNA polymerase γ
 during mtDNA replication. *Nucleic Acids Research*, 44(12), 5861–5871.
- 1479 https://doi.org/10.1093/nar/gkw468
- van Goethem, G., Dermaut, B., Löfgren, A., Martin, J.-J., & van Broeckhoven, C. (2001).
 Mutation of POLG is associated with progressive external ophthalmoplegia characterized
 by mtDNA deletions. *Nature Genetics*, *28*(3), 211–212. https://doi.org/10.1038/90034
- 1483 Venables, W. N., & Ripley, B. D. (2002). *Modern Applied Statistics with S* (Fourth). Springer.
- 1484 Walker, M. A., Lareau, C. A., Ludwig, L. S., Karaa, A., Sankaran, V. G., Regev, A., & Mootha, V. K.
- (2020). Purifying Selection against Pathogenic Mitochondrial DNA in Human T Cells. *New England Journal of Medicine*, *383*(16), 1556–1563.
- 1487 https://doi.org/10.1056/nejmoa2001265

- 1488 Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., &
- 1489 Nikoskelainen, E. K. (1988). Mitochondrial DNA Mutation Associated with Leber's 1490 Hereditary Optic Neuropathy. *Science*, *242*(4884), 1427–1430.
- 1491 https://doi.org/10.1126/SCIENCE.3201231
- Wanagat, J., Cao, Z., Pathare, P., & Aiken, J. M. (2001). Mitochondrial DNA deletion mutations
 colocalize with segmental electron transport system abnormalities, muscle fiber atrophy,
 fiber splitting, and oxidative damage in sarcopenia. *FASEB Journal*, *15*(2), 322–332.
 https://doi.org/10.1096/fj.00-0320com
- Wang, G., Sarkar, A., Carbonetto, P., & Stephens, M. (2020). A simple new approach to variable
 selection in regression, with application to genetic fine mapping. *Journal of the Royal Statistical Society: Series B (Statistical Methodology), 82*(5), 1273–1300.
 https://doi.org/10.1111/RSSB.12388
- Wanrooij, P. H., Uhler, J. P., Shi, Y., Westerlund, F., Falkenberg, M., & Gustafsson, C. M. (2012).
 A hybrid G-quadruplex structure formed between RNA and DNA explains the extraordinary
 stability of the mitochondrial R-loop. *Nucleic Acids Research*, *40*(20), 10334.
- 1503 https://doi.org/10.1093/NAR/GKS802
- Wanrooij, P. H., Uhler, J. P., Simonsson, T., Falkenberg, M., & Gustafsson, C. M. (2010). G quadruplex structures in RNA stimulate mitochondrial transcription termination and
 primer formation. *Proceedings of the National Academy of Sciences of the United States of America*, 107(37), 16072–16077. https://doi.org/10.1073/pnas.1006026107
- Wei, W., Schon, K. R., Elgar, G., Orioli, A., Tanguy, M., Giess, A., Tischkowitz, M., Caulfield, M. J.,
 & Chinnery, P. F. (2022). Nuclear-embedded mitochondrial DNA sequences in 66,083
 human genomes. *Nature*. https://doi.org/10.1038/s41586-022-05288-7
- Weissensteiner, H., Forer, L., Fendt, L., Kheirkhah, A., Salas, A., Kronenberg, F., & Schoenherr, S.
 (2021). Contamination detection in sequencing studies using the mitochondrial phylogeny.
 Genome Research, *31*(2), 309–316. https://doi.org/10.1101/GR.256545.119
- Weissensteiner, H., Pacher, D., Kloss-Brandstätter, A., Forer, L., Specht, G., Bandelt, H. J.,
 Kronenberg, F., Salas, A., & Schönherr, S. (2016). HaploGrep 2: mitochondrial haplogroup
 classification in the era of high-throughput sequencing. *Nucleic Acids Research*, 44(W1),
 W58–W63. https://doi.org/10.1093/nar/gkw233
- Xuan, H. P., Farge, G., Shi, Y., Gaspari, M., Gustafsson, C. M., & Falkenberg, M. (2006).
 Conserved sequence box II directs transcription termination and primer formation in mitochondria. *Journal of Biological Chemistry*, *281*(34), 24647–24652.
 https://doi.org/10.1074/jbc.M602429200
- Yang, S. Y., Castellani, C. A., Longchamps, R. J., Pillalamarri, V. K., O'Rourke, B., Guallar, E., &
 Arking, D. E. (2021). Blood-derived mitochondrial DNA copy number is associated with
 gene expression across multiple tissues and is predictive for incident neurodegenerative
 disease. *Genome Research*, *31*(3), 349–358. https://doi.org/10.1101/GR.269381.120
- Zhou, W., Kanai, M., Wu, K. H. H., Rasheed, H., Tsuo, K., Hirbo, J. B., Wang, Y., Bhattacharya, A.,
 Zhao, H., Namba, S., Surakka, I., Wolford, B. N., Io Faro, V., Lopera-Maya, E. A., Läll, K.,
 Favé, M. J., Partanen, J. J., Chapman, S. B., Karjalainen, J., ... Neale, B. M. (2022). Global
 Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. *Cell Genomics*, 2(10), 100192. https://doi.org/10.1016/J.XGEN.2022.100192

1531 Zhou, W., Nielsen, J. B., Fritsche, L. G., Dey, R., Gabrielsen, M. E., Wolford, B. N., LeFaive, J.,

- 1532 VandeHaar, P., Gagliano, S. A., Gifford, A., Bastarache, L. A., Wei, W. Q., Denny, J. C., Lin,
- 1533 M., Hveem, K., Kang, H. M., Abecasis, G. R., Willer, C. J., & Lee, S. (2018). Efficiently
- 1534 controlling for case-control imbalance and sample relatedness in large-scale genetic
- association studies. *Nature Genetics 2018 50:9, 50*(9), 1335–1341.
- 1536 https://doi.org/10.1038/s41588-018-0184-y
- 1537
- 1538